November 2015

How Family Physicians in Saskatchewan Make Lung Cancer Screening Decisions

Nusrat Jamil
The University of Western Ontario

Supervisor
Dr Tom Freeman
The University of Western Ontario

Joint Supervisor
Dr Bridget Ryan
The University of Western Ontario

Graduate Program in Family Medicine

A thesis submitted in partial fulfillment of the requirements for the degree in Master of Clinical Science

© Nusrat Jamil 2015

Follow this and additional works at: http://ir.lib.uwo.ca/etd
Part of the Medicine and Health Sciences Commons

Recommended Citation
http://ir.lib.uwo.ca/etd/3341

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of Scholarship@Western. For more information, please contact tadam@uwo.ca.
HOW FAMILY PHYSICIANS IN SASKATCHEWAN MAKE LUNG CANCER SCREENING DECISIONS

(Thesis Format: Monograph)

By

Dr. Nusrat Jamil

Graduate Program in Family Medicine

A thesis submitted in partial fulfillment of the requirements for the degree of Master of Clinical Science (MCISc) in Family Medicine

The School of Graduate and Postdoctoral Studies
The University of Western Ontario
London, Ontario, Canada

© Nusrat Jamil 2015
Abstract

**Aims:** This study explored family physicians’ (FPs) stated practices and decision-making for lung cancer screening.

**Methods:** Cross-sectional survey of a stratified random sample of Saskatchewan FPs using single item questions and simulated clinical scenarios.

**Findings:** Wide variations in FPs’ lung cancer screening practices exist in their decision to screen and choice of screening test. Certain physician, patient and non-medical factors influence FPs’ decision-making contrary to their perception of guidelines.

**Conclusions:** The high self-reported prevalence and measured inclination to screen in clinical scenarios contrary to prevailing guidelines adds unnecessary health care costs and has potential to cause harm.

**Significance:** First and unique study regarding lung cancer screening in family practice in Canada. It contributes to the literature about existing FP practices and decision-making regarding lung cancer screening and highlights implications to health care cost, patient care and CME initiatives.

**Keywords:** Lung Cancer Screening, Decision-making, Clinical Practice Guidelines, Family Medicine.
Acknowledgements

I wish to acknowledge the support of my supervisors Dr Thomas Freeman and Dr Bridget Ryan for their time and invaluable advice.

I also wish to acknowledge the supervision and guidance of Dr John Feightner and Dr Judith Brown in the initial part of the study.

I also wish to thank Rhonda Bryce, University Of Saskatchewan for her essential help with analysis of the data.

Finally, I wish to acknowledge the contribution of my husband Ken and my children Cameron, Sean and Joseph to this thesis and to my life.
Dedication

This thesis is dedicated to my father whose vision has always guided me and to my children Cameron, Sean and Joseph and to my niece Uzma Safia Jamil, whose quest for knowledge inspired me to complete this thesis.
Table of Contents

Abstract ............................................................................................................................... ii
Acknowledgements .............................................................................................................. iii
Dedication ............................................................................................................................. iv
Table of Contents ................................................................................................................ v
List of Figures ................................................................................................................... vii
List of Tables ................................................................................................................... viii
List of Acronyms, Abbreviations and Terminology .......................................................... ix
Chapter 1 Introduction ........................................................................................................ 1
  1.1 Chapter Overview ..................................................................................................... 1
  1.2 Literature Review ..................................................................................................... 2
    1.2.1 Significance of Lung Cancer .............................................................................. 2
    1.2.2 Lung Cancer Screening ...................................................................................... 2
    1.2.3 Issues regarding Screening ................................................................................. 6
    1.2.4 Physicians’ Attitudes about Screening In General ............................................. 7
    1.2.5 Physician attitude towards Cancer Screening ..................................................... 8
    1.2.6 Physicians’ attitudes and practices regarding Lung Cancer Screening .............. 9
    1.2.7 Physicians’ attitudes towards use of Guidelines ............................................... 10
    1.2.8 Influence of Guidelines on Physician Behaviour ............................................. 11
    1.2.9 Current Evidence about Guidelines for Lung Cancer Screening ..................... 12
    1.2.10 Post Survey – Recent Literature Summary..................................................... 13
  1.3 Identification of Research Opportunity................................................................... 14
  1.4 Research Questions ................................................................................................. 15
  1.5 Objectives ................................................................................................................ 16
Chapter 2 Methods............................................................................................................ 18
  2.1 Introduction ............................................................................................................. 18
  2.2 Design ...................................................................................................................... 18
  2.3 Sample ..................................................................................................................... 18
    2.3.1 Inclusion Criteria .............................................................................................. 19
    2.3.2 Exclusion Criteria............................................................................................. 19
  2.4 Survey Questionnaire Development........................................................................ 19
  2.5 Variables .................................................................................................................. 19
    2.5.1 Outcomes .......................................................................................................... 19
    2.5.2 Predictor Variables ........................................................................................... 20
  2.6 Data Collection........................................................................................................ 22
  2.7 Data Entry ............................................................................................................... 22
  2.8 Data Analysis .......................................................................................................... 23
  2.9 Reliability and Validity ........................................................................................... 24
  2.10 Ethics Approval..................................................................................................... 24
Chapter 3 Results .............................................................................................................. 25
  3.1 Introduction ............................................................................................................. 25
  3.2 Physician Factors and Screening Behaviour ........................................................... 27
  3.3 Physician Attitudes & Practices by Screening Group............................................. 29
  3.4 Physicians’ Perceptions of Lung Cancer Screening Guidelines ............................. 32
  3.5 Choice of Screening Test among Screeners by patient’s smoking status ............... 34
  3.6 Influence of Non-medical Factors on Screening Behaviour .................................... 35
3.7 Influence of Lung Cancer in Self or Close Relative and Smoking on Screening Behaviour ......................................................................................................................36
3.8 Influence of Patient Factors in Clinical Vignettes .................................................. 37
3.9 Influence of Patient Factors in Clinical Vignettes .................................................. 38
3.10 Proportion of participants screening within each scenario by perception of screening recommendation ........................................................................................................ 42
3.11 Conclusions ........................................................................................................... 46

Chapter 4 Discussion ........................................................................................................ 48
4.1 Introduction ............................................................................................................. 48
4.2 Physician Factors and Screening Behaviour ........................................................... 48
4.3 Influence of Physician Attitudes on Screening Behaviour ..................................... 49
4.4 Physicians’ Perception of Lung Cancer Screening Guidelines ................................ 50
4.5 Choice of Screening Test among Screeners .......................................................... 51
4.6 Influence of Non-medical Factors on Screening Behaviour .................................. 52
4.7 Influence of Lung Cancer in Self or Anyone Close and Smoking Status on Screening Behaviour ........................................................................................................ 52
4.8 Influence of Patient Factors in Clinical Scenarios .................................................. 53
4.9 Implications ............................................................................................................ 55
4.10 Strengths ............................................................................................................... 56
4.11 Limitations ............................................................................................................ 56
4.12 Direction for future research ................................................................................. 57

References ......................................................................................................................... 58
Appendix A Lung Cancer Screening Survey Instrument ................................................. 66
Appendix B Letter of Information .................................................................................... 73
Appendix C Analysis of Tudiver Survey Instrument ....................................................... 76
  C.1 Analysis.............................................................................................................. 76
Appendix D Tudiver Survey Instrument ........................................................................... 78
Appendix E Detailed Methods for Questionnaire Development ..................................... 87
  E.1 Questionnaire Design Methodology ................................................................... 87
  E.2 Questionnaire Items ............................................................................................ 87
    E.2.1 Section II Items to classify physicians as Screeners or Non-Screeners ...... 88
    E.2.2 Section III Clinical Case Vignettes ............................................................. 89
  E.3 Reliability and Validity ...................................................................................... 90
Appendix F Ethics Approval ............................................................................................ 91
Appendix G Curriculum Vitae .......................................................................................... 93
List of Figures

Figure 1-1 Conceptual FP Lung Cancer Screening Decision Making Model .................. 17
List of Tables

Table 1-1 National Lung Cancer Screening Guidelines ..................................................... 5
Table 1-2 Guidelines from Canadian Sources ................................................................... 5
Table 3-1 Physician Characteristics ............................................................................... 26
Table 3-2 Physician Factors and Screening Behaviour .................................................... 28
Table 3-3 Physicians’ agreement with statements on attitudes and practices by screening group .......................................................................................................................... 30
Table 3-4 Perceptions of Lung Cancer Screening Guidelines ........................................... 33
Table 3-5 Choice of Screening Test by Smoking Status among Screeners (n=34) ......... 34
Table 3-6 Physician agreement that non-medical factors would influence test ordering behaviour ................................................................................................................................ 35
Table 3-7 Close experience with lung cancer and smoking status ................................... 36
Table 3-8 Proportions of participants screening using CXR, CT, or sputum cytology in uncomplicated and complicated scenarios ........................................................................... 37
Table 3-9 Comparison of the proportions of participants screening using CXR, CT, or sputum cytology in uncomplicated versus complicated patient-physician interactions .................................................................................. 40
Table 3-10 Proportion of participants screening within each scenario by perception of screening recommendation ........................................................................................................... 44
List of Acronyms, Abbreviations and Terminology

- **Attitude**: a pattern of mental views established by cumulative prior experience
- **Behaviour**: what physicians do in a simulated or actual clinical setting
- **Beliefs**: what physician holds as true, a physician factor
- **CCFP**: Certification in Family Medicine, College of Family Physicians of Canada
- **CFPC**: College of Family Physicians of Canada
- **CME**: continuing medical education
- **CPSS**: College of Physicians and Surgeons of Saskatchewan
- **CRC**: colorectal cancer
- **CT**: computed tomography imaging
- **CTFPHC**: Canadian Task Force on Preventative Health Care
- **CXR**: chest X-ray
- **DRE**: digital rectal exam
- **EMR**: electronic medical record (computer program)
- **FP**: family physician
- **GP**: general practitioner
- **LDCT**: low dose spiral CT
- **Perception**: what physician believes or perceives as true
- **Practices**: actual behaviour in a clinical setting
- **PCP**: primary care physician
- **USPSTF**: United States Preventative Services Task Force
- **UWO**: University of Western Ontario
Chapter 1
Introduction

1.1 Chapter Overview

This chapter describes the significance of lung cancer, guidelines, decision-making and practice variations in behaviour of family physicians (FPs) regarding lung cancer screening. The literature reports variation in medical practice that is not based on carefully constructed guidelines. This variation is seen in procedures where evidence is unclear or conflicting as well as where there is a clear consensus in guidelines.\(^1\) Factors such as anxiety about cancer and expectation expressed by patients for a screening test influence FPs to order screening tests.\(^2\)

The decision-making context in which screening decisions are made is explored. Issues about screening and guidelines are highlighted; physician’s attitude towards screening in general, cancer screening, lung cancer screening, use of guidelines and variation in their practice behaviour are presented.

The variation in guidelines, risk of lung cancer and limited detection and treatment options raise questions about FPs decision-making on lung cancer screening for their patients. For example, do they screen for lung cancer? If they do, how often do they screen and which screening tests are ordered? Additionally the literature lacks evidence on how those decisions are made. Specifically, what factors influence a FP to order or not order a screening test for lung cancer? Do patient’s preferences, fears and expectations, physician factors and the influence of colleagues, personal experience with cancer and availability, access and cost of the screening test influence their decision making for lung cancer screening?

This chapter concludes with a summary, which synthesizes the rationale for research based on gaps in knowledge and evidence presented in the literature review. Finally, the study research questions are formulated, corresponding research objectives defined and a conceptual FP lung cancer screening decision making model introduced.
1.2 Literature Review

1.2.1 Significance of Lung Cancer

Lung cancer accounts for the highest cancer mortality rate for both men and women according to American Cancer Society data. The 2011 statistics show it is the leading cause of cancer death for men aged 40 and older, and for women aged 60 and older. The five-year survival rate is only 16% and 90% with the disease die from it. Smoking is the most important risk factor causing 85% of U.S. lung cancer cases. The primary reason for such a poor cure rate is that nearly all lung cancers are found at a very late stage, making curative treatment impossible. Even with recent advances in detection, "screening cannot prevent most lung-cancer deaths, and smoking cessation remains essential."

1.2.2 Lung Cancer Screening

An editorial on the status of lung cancer screening stressed the need for effective clinical strategies for aiding patients with lung cancer, which has the highest incidence and mortality among all cancers. Some groups, for example, the US Lung Cancer Alliance, advocate use of computed tomography (CT) scan for lung cancer screening. This position was clearly against the best available screening guidelines (at the time of the present study) which did not recommend (i.e. cited insufficient evidence for or against) use of CT or chest X-ray (CXR) respectively. Only recently, the United States Preventative Services Task Force (USPSTF) 2014 Lung Cancer screening recommendation statement updated their 2004 recommendation statement to recommend annual CT Scan for high risk patients. Those at high risk were defined as asymptomatic current smokers or those who had quit within the last 15 years, and those between the ages of 55 years and 80 years having a 30 pack per year smoking history. This guideline was graded as category B meaning "there is high certainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to substantial."
The literature reports physician ordering of CXR as a test for lung cancer screening despite the fact that guidelines were against its use. It may be the case that certain patient factors, such as patient anxiety, diagnosis, or death in close friend or family member, and patient demands play a vital role in the final decision to order or not order a screening test for lung cancer.

Research is required to study the behaviour of FPs regarding lung cancer screening and to explore what factors influence their decision-making. Factors influencing decision making for cancer screening indicate physician factors, patient factors, and patient-physician relationship are key to finding common ground and lead toward a mutual decision on whether or not to screen for several cancers. However, this model emerged from studying cancer screening decision-making for cancers such as prostate, colorectal and breast cancer but did not study lung cancer decision making. The goal of that study was to understand the decision making process for cancers where National Guidelines from two or more sources are different.

One study utilized a survey questionnaire to explore attitudes, beliefs and behaviours on lung cancer screening. The researchers concluded that a substantial number of physicians screen for lung cancer using CXR (25%) despite the fact that it was not recommended. They also discovered that pulmonologists screen more than family practitioners and those with more years in practice screen more frequently than those with fewer years in practice. Further research is required to identify the factors that influence decision-making for lung cancer screening.

Screening by physicians contrary to the recommended evidence-based guidelines has potential risks such as increased incidence of false positives, unnecessary investigations, radiation exposure, psychological stress and increased cost without any benefit.

It is important to see if the factors affecting decision making for other cancers where guidelines are conflicting or the evidence is unclear also apply to the case of lung cancer screening.
After many years of research, there is no evidence proving the efficacy of CXR as a screening test for lung cancer. The Memorial-Sloan Kettering, the Johns Hopkins and the Mayo Lung Project trials evaluated CXR as a stand alone screening test or with sputum cytology to screen for lung cancer. Follow-up did not show a difference in lung cancer incidence or mortality.

Prevailing national guidelines for lung cancer screening (at the time of the present study) differed in their advice about the use of CXR. The Canadian Task Force on Preventive Health Care (CTFPHC) guidelines recommended against screening for lung cancer using CXR and concluded there was insufficient evidence to screen with low-dose computed tomography (LDCT). The USPSTF stated “the evidence is insufficient to recommend for or against screening asymptomatic persons for lung cancer with either low-dose computerized tomography (LDCT), chest x-ray (CXR), sputum cytology, or a combination of these tests.”

Nevertheless, in discussions with physician colleagues and departments of radiology, it is common to find CXR requisitions for asymptomatic patients for annual or periodic exams, which can be assumed to be for screening purposes. To date, there are no formal data collected to see whether these tests are being ordered for screening purposes in Canada. There is limited research regarding factors that may influence physician screening behaviour on lung cancer screening specifically. There have been studies on physician behaviour on breast, prostate and colorectal cancer.

Guidelines from various Canadian sources differ in their recommendations for lung cancer screening. The Saskatchewan Health Services Utilization and Research Commission and British Columbia Council recommended against use of CXR. However the Manitoba Consensus Group recommended CXR for screening differing from the prevailing guidelines for lung cancer screening.

Lung cancer risk among heavy smokers may be as high as 30% compared to non-smokers. Other risk factors include positive family history of lung cancer and a history of chronic obstructive pulmonary disease (COPD).
Studies reveal LDCT as a promising screening method for lung cancer detection as part of periodic health examinations. This could be offered to patients who are identified at high risk for lung cancer. However, the radiation exposure may be harmful.

The literature does not support lung cancer screening with CXR or with sputum cytological examination. Risk of inducing anxiety in false positive cases will cause unnecessary further testing and radiation. Further research is needed for identifying an appropriate approach to screening in clinic practice.

Table 1 and 2 summarize the variation in national recommendations for lung cancer screening at the time of this study.

**Table 1-1 National Lung Cancer Screening Guidelines**

<table>
<thead>
<tr>
<th>Screening Test</th>
<th>CTFPHE</th>
<th>USPSTF</th>
<th>Australia</th>
<th>NHS England</th>
</tr>
</thead>
<tbody>
<tr>
<td>CXR</td>
<td>Recommend Against</td>
<td>Insufficient Evidence</td>
<td>Recommend Against</td>
<td>No Recommendation</td>
</tr>
<tr>
<td>CT Scan</td>
<td>Insufficient Evidence</td>
<td>Insufficient Evidence</td>
<td>Recommend Against</td>
<td>No Recommendation</td>
</tr>
<tr>
<td>Sputum Cytology</td>
<td>No Recommendation</td>
<td>Insufficient Evidence</td>
<td>Recommend Against</td>
<td>No Recommendation</td>
</tr>
</tbody>
</table>

**Table 1-2 Guidelines from Canadian Sources**

<table>
<thead>
<tr>
<th>Screening Test</th>
<th>CTFPHE</th>
<th>British Columbia Council</th>
<th>Saskatchewan Health Services Utilization and Research Commission</th>
<th>The Manitoba Consensus</th>
</tr>
</thead>
<tbody>
<tr>
<td>CXR</td>
<td>Recommend Against</td>
<td>Recommend Against</td>
<td>Recommend Against</td>
<td>Recommend</td>
</tr>
<tr>
<td>CT Scan</td>
<td>Insufficient Evidence</td>
<td>No Recommendation</td>
<td>Recommend Against</td>
<td>Recommend</td>
</tr>
<tr>
<td>Sputum Cytology</td>
<td>No Recommendation</td>
<td>Recommend Against</td>
<td>Recommend Against</td>
<td>Recommend Against</td>
</tr>
</tbody>
</table>

Despite the fact that, with one exception (Manitoba), current recommendations are against the use of CXR as a screening test for lung cancer, some FPs do screen their patients. These significant variations in recommendations and practice behaviour identifies a gap and indicates that further research is needed to improve evidence based
guidelines that are implementable and will improve preventive care in family practice.\textsuperscript{18,26}

1.2.3 Issues regarding Screening

The literature suggests that a number of factors are involved in decision-making around screening in general:\textsuperscript{10,27-29}

**Physician Perspective:**
- Physicians are a resource to their patients. Physicians prefer to screen, as they like to prevent life-threatening illness for their patients.
- Physicians want to be rated as responsible physicians by their communities
- It is important to build patient-physician relationship
- Physicians may want to protect against litigation if it will come from not offering screening tests and by following available best practice guidelines that could prevent their patients from illness like cancer

**Patient Perspective:**
- Patients generally expect their physicians to diagnose illnesses
- Patients expect their physician to diagnose cancers early by ordering lab tests and radiological diagnostic tests for their periodic health exams
- Patients also appreciate and sometimes expect their physicians to educate them regarding preventative strategies for cancers

**Issues regarding Guidelines**
- Several guidelines are available as practice resources
- Some are conflicting and are unclear
- Some are clear, however may conflict with physicians practice experience and don’t take into account the patient’s perspectives.

**Need for Screening**
- Saves healthcare dollars by detecting disease early
- Savings in cost of treatment through earlier diagnosis
• Savings in lives saved
• Savings in ailments and disabilities in relatives and significant others

1.2.4 Physicians’ Attitudes about Screening In General

The literature\textsuperscript{27} indicates that physicians perform screening tests more often than recommended or sometimes do not follow current practice recommendations. The CTFPHC and USPSTF screening guidelines are considered the standard for prevention. Even when these screening guidelines are thought to be followed, deviation occurs. The following reasons were identified:\textsuperscript{27}

• Lack of knowledge of current guidelines.
• Patient’s expectation or demand as seen in the case of mammography.
• High volume of patients who are at risk for developing cancer.
• The physician has concerns regarding the sensitivity and effectiveness of screening methods.
• The guidelines that make recommendations also comment on the evidence being insufficient, which may decrease physician confidence in the recommendation.
• There is an economic benefit for the physician from ordering frequent tests for screening.

An American study used online surveys to determine attitudes of physicians regarding cholesterol and heart disease. It found that most of the physicians surveyed, (who were from pre-existing independent panels) felt they followed the National Cholesterol Education Program Adult Treatment Panel III guidelines, but felt that other physicians did not follow them. The attitudes of physician and consumers were similar in recognition of the significant health link between cholesterol and coronary artery disease, but differ in why patients do not take prescription medications.\textsuperscript{30}

With a lack of knowledge about what actually influences physicians’ attitudes toward screening, an American study examined the influence of actual or perceived state policy on pediatricians’ attitudes toward screening. It found variations in support for the
screening guidelines considered in the study. It showed that pediatricians who believed
the State had a policy of screening were more supportive of screening.\textsuperscript{31}

In the absence of literature on the topic, an American study was undertaken to determine
FPs’ knowledge about sexually transmitted infections (STIs) management. The study
demonstrated that physicians with good knowledge of STI guidelines were more likely to
do routine screening of women at high risk for contracting Chlamydia infections. It was
also identified that lack of knowledge was a barrier to following recommended screening
for STIs. Educational and dissemination interventions were recommended.\textsuperscript{32}

A U.S. study found there was substantial variation across medical offices in Chlamydia
screening for at risk women. Further research was suggested to understand predictors of
better office performance with the goal of more effective interventions promoting
screening.\textsuperscript{33}

FPs’ screening practices vary depending on the medical condition being screened and
FPs’ beliefs and practices. A study on FPs’ hepatitis C management found little use of a
standardized history-taking form for disease-specific screening, something shown to be
necessary, to screen for other medical conditions.\textsuperscript{34}

In summary, the literature shows physicians’ screening practices vary and differ from
guideline recommendations. Physician attitudes about screening in general are influenced
by knowledge (or lack thereof), differing recommendations, perceptions of state policy
and sometimes personal preference.

1.2.5 Physician attitude towards Cancer Screening

An Alberta, Canada study explored the attitudes of specialists for colorectal cancer
(CRC) screening practices, the year after a national CRC screening guideline was
released. The results showed specialty-based variations in their practices and significant
overall common practice and personal beliefs/attitudes for self-treatment which went
against the CTFPHE guidelines, in which colonoscopy was not recommended.\textsuperscript{35} This
might be because specialists see a pre-screened population of patients and screening
guidelines that might be appropriate for primary care may not necessarily be appropriate for secondary care.

A U.S. survey study examined physician attitudes to prostate cancer screening at a health care facility for Veteran Affairs. The survey questionnaire asked what risk factors influence FP’s’ decision to screen patients for prostate cancer. The study concluded FPs recognized elevated risk for African-Americans and a family history of prostate cancer but frequently screened elderly or patients with a limited life expectancy, which was not within guidelines.36

An Italian survey study explored CRC screening knowledge, attitudes and practices of all general practitioners (GPs) in Lazio, Italy. The response rate was 59%. Ninety four percent believed CRC was preventable. Knowledge was higher in physicians using screening guidelines. Twenty-five percent recommended screening tests, 22% did not recommend and 47% over-recommended. The study investigators felt the low response rate was indicative of GP’s lack of interest in screening.37

In summary, lack of interest in screening, logistical barriers and a lack of awareness of cancer information and research services were identified as factors relating to low cancer screening rates by FPs.

1.2.6 Physicians’ attitudes and practices regarding Lung Cancer Screening

Physicians’ attitudes and beliefs towards screening for lung cancer have been recently studied in a U.S. prospective descriptive survey9, mailed to FPs, internists and pulmonologists. The response rate was 303/3000 (10%) with 71% FPs and 29% pulmonologists. Physicians were identified as high screeners, low screeners or no screeners. Physicians were also asked to describe factors that influence ordering of screening tests.

The study showed the relative importance of factors (highest to lowest) to physicians when assessing a screening program:

1. If there was proven clinical efficacy
1. If the test was recommended by USPSTF
2. If the test was sensitive
3. If randomized control trials improved mortality rate
4. If the test was cost effective

Despite the low response rate, the researchers concluded that a substantial number of physicians screen for lung cancer using CXR (25%) even though guidelines are against its use as a screening test. Pulmonologists screen more than family practitioners do and the number of years in clinical practice was directly related to screening behaviour. “Screening outside accepted guidelines has potential risks including false-positive results, unnecessary invasive procedures, radiation exposure, psychological stress, and increased costs to the health care system.”

A large scale U.S. national study of FP's showed lung cancer screening tests such as CXR were commonly ordered even though unsupported by guidelines. Other research shows FP's screen for lung cancer, including one study which found 10-90% of PCPs reporting they do so.

A U.S. qualitative study of physicians’ lung cancer screening practices used telephone-conducted focus groups. Participants consisted of 17 internists and 11 FP's. That study identified seven factors influencing physicians’ decision to screen for lung cancer: five physician factors and two patient factors. Physician factors were perception of the effectiveness of screening; guideline recommendations; practice experience; perception of patient’s risk factors for lung cancer and fear of litigation. Patient factors were patient request for screening and ability to pay for the screening procedure.

### 1.2.7 Physicians’ attitudes towards use of Guidelines

Family physicians play a vital role in cancer screening. The attitudes of family physicians towards guidelines have been explored. A study by the Ottawa Health Research Institute explored the family physician’s views on cancer screening guidelines. It was found that guidelines sometimes add controversy and barriers to the decision-making process. FP’s expect guideline developers to provide them with the resources to help in...
their decision-making process by providing clear guidelines in an easy-to-use format on topics identified by them as relevant to their practice.

Since FPs involve their patients in care, including patient involvement in decision-making, FPs expect guidelines/decision-making tools be made available to them in an interactive format which they can use with their patients in the office setting.44

A German study of general practitioners and internists studied knowledge of secondary prevention of coronary heart disease. It also studied their perception of guidelines and how that perception influenced their treatment practices. Results showed that increased knowledge of guidelines was directly related to improved management of risk factors for heart disease. However, many physicians who were aware of guidelines chose to treat in a way that differed from guidelines.45

In a study that assessed knowledge and beliefs of American physicians and how they influenced their practices in managing colorectal cancer screening, it was found that most providers recommended screening-guidelines, but patient refusal was common. Usual practice often did not follow evidence-based guidelines.46

A systematic review of studies on clinician’s attitudes to clinical practice guidelines was conducted covering years 1990-2000.47 Clinicians agreed guidelines were helpful and useful as educational tools and believed they tend to improve quality of care. However, they also found guidelines to be impractical; some felt they were very rigid and inapplicable to individual patient situations. They also felt guidelines reduced physician autonomy and were oversimplified. Most expressed the view that guidelines are intended to cut costs in healthcare. Some also feared that use of guidelines may increase litigation.47

1.2.8 Influence of Guidelines on Physician Behaviour

Studies have been conducted to understand the influence of guidelines on physician behaviours and practices. For example, a US survey study was conducted to explore FPs’ attitudes and practices regarding Periodic Health Exam. The study revealed that FPs do
not follow recommendations to use more selective health care approaches for prevention.⁴⁸

Physician factors may affect screening guideline compliance. Compliance with American Cancer Society CRC screening guidelines was associated with physician’s perception of risk for CRC in one study.⁴⁹

A U.S. study assessed the knowledge, perception, and behaviour of family physicians regarding management of dyslipidemia. The study found variability in all three among family physicians and also an overall variability in adherence to guidelines.⁵⁰

All FPs in Newfoundland and Labrador, Canada were surveyed on their prostate cancer screening practices, attitudes and continuing medical education (CME) preferences. The study found physicians were supportive of screening, but their beliefs and practice varied - one half questioned the reliability and evidence to support digital rectal exam (DRE) for screening, and one third questioned both DRE and PSA testing, motivating a need for CME to address identified issues with prostate screening.⁵¹

In summary, physicians’ practices vary from one another and may differ from guidelines. Physicians have a wide variation in knowledge, beliefs and practice patterns. In general, physicians were supportive of screening, however, their beliefs and practices varied from guideline recommendations. They also questioned the evidence supporting the guidelines.

### 1.2.9 Current Evidence about Guidelines for Lung Cancer Screening

At the time the survey was completed (2012), the prevailing guideline from the Canadian Task Force on Preventive Health Care (CTFPHC)⁸ concluded that “there is fair evidence to recommend against screening asymptomatic people for lung cancer using chest radiographic examination (D recommendation).”⁸, p1

The CTFPHC concluded “there is insufficient evidence (in quantity and/or quality) to make a recommendation as to whether spiral CT scanning should be used for screening
asymptomatic people for lung cancer. However, other factors may influence decision-making. (I recommendation)\(^8\), p1

At the time the survey was completed, the prevailing guideline from the U.S. Preventative Services Task Force (USPSTF) was the 2004 recommendation for lung cancer screening, stating that “the evidence is insufficient to recommend for or against screening asymptomatic persons for lung cancer with either low-dose computerized tomography (LDCT), chest x-ray (CXR), sputum cytology, or a combination of these tests. This is a grade I recommendation.”\(^7\), p738

The current Cancer Council of Australia health guideline states “No forms of population screening for lung cancer, including regular chest radiography, with or without sputum cytology even in high-risk groups, have been shown to improve outcomes and screening is not recommended. In view of the limited information available on outcome, helical CT screening for lung cancer is not recommended except in the context of a well-designed clinical trial.”\(^52\), pxiv

In the 2014 update of their 2004 recommendation, the USPSTF\(^4\) recommended certain people at high risk for lung cancer be screened with low dose CT scan annually. The high-risk people were defined as current smokers or smokers who have quit within the last 15 years, in adults aged 55-80 who have a 30 pack-year smoking history. A pack year was defined as smoking an average of one pack of cigarettes per day for one year. Screening should be discontinued once a person has not smoked for 15 years or developed a health problem that substantially limits life expectancy or the ability or willingness to have curative treatment for lung cancer. This guideline was graded as category B meaning “there is high certainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to substantial.”\(^4\), Appendix, Table 1

1.2.10 Post Survey – Recent Literature Summary

Subsequent to survey instrument development and data collection, recent related research was published. A Scopus search was conducted to bring the literature review up to date. It found 25 articles that cited Haggerty\(^2\), the most recent publication in the series of
research that this thesis extends\textsuperscript{2,10,28,53}. Three have relevance to physician decision making. One\textsuperscript{54} investigated which factors influenced physician decision to order PSA screening tests. Although factors included some of those studied in this thesis research, others were dissimilar, and the survey methods and analysis were dissimilar and unsuited for adaptation or comparison. Another study\textsuperscript{55} explored which patient and physician factors influenced cervical cancer screening over and under use. This was not a survey study, but instead collected actual ordering data. The third study\textsuperscript{56} involved a survey instrument completed by both physician and patient regarding attitudes to shared care and influence on specialist referrals. The instrument and methods were dissimilar to that used in the current study.

Updates to guidelines for lung cancer screening were also made, with modified recommendations. The changes have already been discussed in section 1.2.9 above.

1.3 Identification of Research Opportunity

Lung cancer is a prevalent cancer and accounts for significant mortality. There are not many helpful strategies available for dealing with lung cancer prevention other than counselling smoking cessation and detection at an earlier stage. There are not many treatments that are very useful for treating lung cancer. FPs have regular contact with the patient population at risk for disease and the physician group most likely to screen for diseases. As their patient population includes smokers, FPs are concerned about them and face the challenge of what can they do which would be helpful in detecting lung cancer at early stages.

In summary, lung cancer is a prevalent disease and those at higher risk, such as those who smoke are frequently attended in family physicians’ offices where screening may be taking place.

The literature has been reviewed in terms of the effectiveness of lung cancer screening tests. Recommendations are conflicting regarding use of screening tests. At best, there is insufficient evidence to recommend routine screening with CXRs. Some guideline panels
have stated there is enough evidence to say that CXR is not effective and have recommended against routine screening while others do recommend it.

Regardless, the literature confirms that some FPs do screen with CXRs. There appears to be a dissonance between what people reviewing the evidence suggest and how certain FPs are behaving. The literature shows a gap between recommendations and behaviour in practice and that there is a need to examine some of the various reasons for this gap. There is also literature that has looked at cancer screening generally and in the context of uncertainty.38,39,43,57

Therefore, to try to understand this gap, it is important to understand how often FPs report they are screening for lung cancer, what screening tests they order and the factors that influence them to behave in a way that is different than some experts have suggested the evidence would indicate or direct.

Understanding this is important for several reasons. In economic terms, if resources are being used that are not effective, then they are not available for other purposes. It will provide insights in terms of helping FPs understand guidelines better and aid in adherence. It will help guideline developers to understand how they might improve adherence to recommendations by understanding how intended users make decisions around screening and the many factors that influence their decision-making.

1.4 Research Questions

The following research questions were explored:

1. What do family physicians practicing in urban and rural Saskatchewan report they do regarding their lung cancer screening practices?

2. Which lung cancer screening test(s) do family physicians practicing in urban and rural Saskatchewan report they use?

3. Which factors influence the decision-making of family physicians practicing in urban and rural Saskatchewan when presented with hypothetical clinical scenarios?
1.5 Objectives

The study objectives were:

1. To estimate the frequency with which FPs order lung cancer screening tests. Data were used to identify two groups of FPs:
   a) *Screeners*, defined as those who report they order lung cancer screening tests for asymptomatic ever smokers;
   b) *Non-Screeners*, defined as those who report they do not order lung cancer screening tests for patients who are asymptomatic ever-smokers.

2. To determine how frequently CXR was ordered as a screening test. Since the CTFPHE recommendations are clearly against the use of CXR as a screening test, the survey specifically questioned about the use of CXR.

3. To determine the factors that influence lung cancer screening decision-making.

This research explored FPs’ reported lung cancer screening behavior based on factors identified in the literature that influenced screening decision-making for other cancers such as breast, colon and prostate. The literature revealed no research to-date that studied the influence of any of these factors on lung cancer screening decision-making in Canada. This study incorporates these factors into a proposed model shown in Figure 1-1.
Figure 1-1 Conceptual FP Lung Cancer Screening Decision Making Model

This illustrates the author’s initial concept of the factors involved in a physician’s lung cancer screening decision-making based on the literature. It illustrates patient, physician and non-medical factors that are identified in the literature as factors influencing cancer-screening decision-making for breast, colon and prostate cancers.\(^2,10\) This study used clinic scenarios in the survey to explore whether these factors also influenced lung cancer decision-making behaviour.
Chapter 2
Methods

2.1 Introduction
The CTFPHC and USPSTF guidelines for lung cancer screening at the time of the study differed slightly but none recommended screening with CXR. However, there is uncertainty about family physicians’ (FPs) lung cancer screening practices in clinical encounters - whether FPs screen for lung cancer, what screening test do they order and how often do they screen despite guideline recommendations.

This study identified whether Saskatchewan FPs screen for lung cancer and what factors influenced them to do so. It consisted of a cross-sectional survey and measured FPs’ responses to self-reported screening behaviour questions and to hypothetical clinical screening scenarios. These two outcomes were analyzed separately.

2.2 Design
This study consisted of a cross-sectional survey with two components:

1. Questions designed to measure physicians’ self-reported behaviour and
2. Hypothetical clinical scenarios designed to determine physician’s intended behaviour in different situations. The data collected from these two components were analyzed separately.

2.3 Sample
The study respondents were FPs practicing in rural, regional and urban areas of Saskatchewan.
2.3.1 Inclusion Criteria

Only physicians who worked more than fifteen hours per week in family practice (i.e. deemed to be full-time) were included. This maintains consistency with the classification used in comparable research by Tudiver et al.\textsuperscript{2}

2.3.2 Exclusion Criteria

Specialist physicians practicing internal medicine, surgery, pulmonology, neurology, pathology, radiology and any other specialities were excluded from the study.

2.4 Survey Questionnaire Development

The method of data collection used was survey via a self-administered paper questionnaire. A mail survey package was developed for distribution, including a letter of information, a survey questionnaire and a stamped return envelope (Appendices A & B).

This study’s objectives were consistent with Tudiver et al. except that they studied breast, colon and prostate screening behaviours of FPs whereas this study specifically explored lung cancer screening behaviour of FPs.

Tudiver’s survey instrument (Appendix C) was adapted because of the benefit of employing a previously validated methodology. The survey was modified to study lung cancer screening behaviour. Appendix D describes the systematic and rigorous adaptations made to the Tudiver survey.

2.5 Variables

2.5.1 Outcomes

Two outcomes were measured:

1. Based on their self-reported screening behaviours, physicians were dichotomized into Screeners and Non-Screeners. We defined Screeners as physicians who
ordered screening tests for lung cancer if they reported they routinely ordered screening tests for asymptomatic patients who are ever-smokers (Section II, question 2a). Similarly, physicians who reported they did not order lung cancer screening tests for asymptomatic ever-smokers were defined as Non-Screeners (Section II, question 2a).

2. Based on their responses to clinical scenarios (Section III), FPs’ intended decision to order a lung cancer screening test with dichotomous variables (yes or no). This was based on six hypothetical scenarios:

a) Scenario 1 was considered uncomplicated.

b) Scenarios 2 to 5 each contained a complicating dynamic: expectation, anxiety, family history, poor patient-physician relationship respectively.

c) Scenario 6 contained all four complicating dynamics.

d) For each scenario, respondents indicated whether they would order any of three possible screening tests: CXR, CT chest and sputum cytology

2.5.2 Predictor Variables

Several characteristics of the physician and non-medical factors have been shown to influence physicians’ screening behaviour. Therefore the self-reported Screeners and Non Screeners were compared by the following independent variables:

1. Physician Factors:

   a) Physician characteristics (as outlined below) (Section IV):

      i. Gender (question 1)

      ii. Age group (question 2)

      iii. Certification by The College of Family Physicians of Canada (CCFP) (question 3)

      iv. Professional membership in the College of Family Physicians of Canada (question 4)

      v. Number of years of family practice (question 5)
vi. Type of practice: solo, group (question 6)

vii. Location of practice: urban vs. non-urban-(regional were coded as non-urban (question 7)

viii. Number of practice hours per week (question 8)

ix. Teaching responsibilities (question 9)

b) Attitudes toward screening (Section II, question 3-13)

c) Perception of guidelines (Section I, questions 1-3)

d) Screening behaviour (Section II, questions 1-2)

2. Non-Medical Factors (Section II, questions 14c-h):

a) Influence of practice colleagues

b) Influence of specialist colleagues

c) Cost of the test

d) Accessibility of test

e) Ease of administration

f) Time constraints

Several patient factors have been identified as the most important determinants of cancer screening decision-making for breast cancer, colorectal cancer and prostate cancer. This study measured if they also influenced the physicians’ decision to screen for lung cancer in hypothetical clinical scenarios. These factors were:

1. Patient Factors, self-reported behaviour (Section II, questions 14a-b):

a) Patient’s expectations to undergo screening

b) Anxiety about having lung cancer

2. Patient Factors, measured behaviour (Section III):

a) Patient’s expectations to undergo screening (Scenario 2)

b) Anxiety about having lung cancer (Scenario 3)
c) Positive family history of lung cancer (Scenario 4)

d) Quality of the patient-physician relationship (Scenario 5)

2.6 Data Collection

A distribution list was generated from the College of Physicians and Surgeons of Saskatchewan registry and the Regional Health Authority administration offices. A stratified sample of FPs who met the inclusion criteria were recruited by mailing them a complete survey package.

To increase the external validity of the study, a high rate of return was desired. The survey was distributed and administered using methods known to enhance physician participation. A revised, step-wise Dillman Method\textsuperscript{58} was used to encourage response:

1. Initial mailing
2. Follow up reminder postcard
3. Second full mailing
4. Phone call reminder

2.7 Data Entry

The Primary Investigator (PI) (author) set up the SPSS data dictionary to correctly code the item types and values needed. Raw data from each uniquely numbered survey questionnaire booklet was entered to produce the SPSS database in preparation for statistical analysis. Some respondents returned partially completed surveys or provided unexpected multiple responses; all were directly coded as provided. Details of how such were accommodated are provided in Chapter 3 Results.

Quality was managed by conducting one hundred percent checking. This was jointly performed post data entry by the PI and an assistant, who compared the coded data with each survey booklet and reconciled any discrepancies.


2.8 Data Analysis

Appropriate analysis of the data collected from the survey was done using SPSS Version 19.

Analysis – Outcome #1

Bivariate analysis examined whether there were any associations between Screeners and Non-Screeners on physician characteristics, attitudes toward screening, perception of guidelines and screening behaviour:

Mann-Whitney-U tests were conducted for continuous independent variables and Chi-Square was used for categorical variables.

Analysis – Outcome #2

Analyses were conducted with the outcome of whether to order one of three possible screening tests in each of the five complicated scenarios. Therefore, 15 comparisons were made (three possible tests by five possible scenarios); each analysis compared decisions made in the uncomplicated scenario against the decision made by the same physician in one of the five complicated scenarios. Due to the repeated nature of the study in that the same participants were asked to provide their screening responses under different conditions, McNemar’s Chi square test was used to assess if the proportion that would screen differed between the each of complicating dynamics (Scenarios 2 to 6) and the uncomplicated scenario (Scenario 1). Because differences in proportions will be the result of participants changing their screening practices under the different conditions, and that these changes can be in either direction (i.e. from “not screen” in the uncomplicated scenario changing to “screen” in complicated or “screen” in uncomplicated changing to “not screen” in complicated), it is the net difference in this change that is statistically important.

Additionally, the influence of recommendation perception on screening behaviour was assessed. Analyses were conducted comparing the proportion of physicians who would screen using each test in each of the scenarios against their perceptions of the guidelines
being recommended or not recommended respectively. Due to the repeated nature of the study, recognizing that the same participants were assessed concerning their practice within multiple scenarios, the association between the perception that the test is recommended and whether or not it was performed was evaluated for each scenario separately. To account for multiple testing, Bonferroni correction was applied to the significance level, with 0.05 divided by 6 scenarios to produce a new alpha of 0.008. Only statistical test results with p-values below this level were considered statistically significant.

2.9 Reliability and Validity

To ensure validity and to ensure appropriateness of the reading level, the survey was piloted on three FPs. This was followed by an interview to improve clarity and comprehensiveness of the questionnaire.

This study also contains a section, consisting of clinical case scenarios where testing is done in the context of a controlled environment, one where independent variables are manipulated to examine decision-making behaviour. In this section, the strength of the internal validity is not felt to be at the expense of external validity; the clinical scenarios presented are intended to model a real-world clinical encounter.

References on questionnaire design and quality assessment were consulted during questionnaire development.59-68

To increase the external validity of the study, a high rate of return was desired. This was promoted in this study by using best practices identified in the literature including administration of the survey using the step-wise revised Dillman Method, discussed in Section 2.6 above.

2.10 Ethics Approval

Ethics approval was obtained from the Research Ethics Board of the University of Western Ontario (Appendix F).
Chapter 3
Results

3.1 Introduction

This study consisted of a cross-sectional survey of family physicians (FPs) practicing in Saskatchewan. Of the 250 FPs contacted, 49 responses were deemed acceptable, after adjusting for surveys which were incomplete on key questions, yielding a final response rate of 20%. The demographics of the final study participants are presented in Table 3-1 (Questionnaire Section IV); available provincial and national data are also listed for comparison. In spite of the small sample size and the low response rate, the characteristics of the study sample are similar to those for Saskatchewan and Canadian FPs, offering some support for generalizability of the findings. However, the sample has a higher proportion of female and rural FPs, compared to the provincial or national populations.

Based on their reported practice behaviour (Section II, question 2a), FPs were divided into two groups, Screeners and Non-Screeners, defined as:

1. **Screeners** - those who report they order lung cancer screening tests for asymptomatic ever-smoking patients;
2. **Non-Screeners** - those who report they do not order lung cancer screening tests for asymptomatic ever-smoking patients.

Out of 49 FPs, 34 (69%) were classified as Screeners and 15 (31%) as Non-Screeners. Of those who screened, CXR was ordered by up to 73% of FPs making it the most commonly ordered screening test contrary to prevailing guidelines.
Table 3-1 Physician Characteristics

<table>
<thead>
<tr>
<th>Physician Factors</th>
<th>All participants (N = 49)**</th>
<th>Total Saskatchewan FP Population (N = 1089)*†</th>
<th>Total Canadian FP Population (N = 34 810)*†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>25 (52%)</td>
<td>(69%)</td>
<td>(59.6%)</td>
</tr>
<tr>
<td>Female</td>
<td>23 (48%)</td>
<td>(31%)</td>
<td>(40.4%)</td>
</tr>
<tr>
<td>Age, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;50 years</td>
<td>32 (67%)</td>
<td>†</td>
<td>†</td>
</tr>
<tr>
<td>≥50 years</td>
<td>16 (33%)</td>
<td>†</td>
<td>†</td>
</tr>
<tr>
<td>CCFP certification, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>24 (50%)</td>
<td>(51.9%)</td>
<td>(54.6%)</td>
</tr>
<tr>
<td>No</td>
<td>24 (50%)</td>
<td>(48.1%)</td>
<td>(45.4%)</td>
</tr>
<tr>
<td>CFPC membership, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>44 (92%)</td>
<td>†</td>
<td>†</td>
</tr>
<tr>
<td>No</td>
<td>4 (8%)</td>
<td>†</td>
<td>†</td>
</tr>
<tr>
<td>Group practice, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>38 (81%)</td>
<td>(82.2%)</td>
<td>(78%)</td>
</tr>
<tr>
<td>No</td>
<td>9 (19%)</td>
<td>(17.8%)</td>
<td>(22%)</td>
</tr>
<tr>
<td>Teaching affiliation, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>21 (44%)</td>
<td>†</td>
<td>†</td>
</tr>
<tr>
<td>No</td>
<td>27 (56%)</td>
<td>†</td>
<td>†</td>
</tr>
<tr>
<td>Practice location, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urban</td>
<td>25 (52%)</td>
<td>(55.3%)</td>
<td>(63%)</td>
</tr>
<tr>
<td>Rural/regional</td>
<td>23 (48%)</td>
<td>(44.7%)</td>
<td>(37%)</td>
</tr>
<tr>
<td>Practice hours/week,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD) ††</td>
<td>30.8 (13.8)</td>
<td>†</td>
<td>†</td>
</tr>
<tr>
<td>Median (IQR) ††</td>
<td>35 (24, 40)</td>
<td>†</td>
<td>†</td>
</tr>
<tr>
<td>Years in practice</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD) ††</td>
<td>13.9 (12.2)</td>
<td>†</td>
<td>†</td>
</tr>
<tr>
<td>Median (IQR) ††</td>
<td>30.8 (13.8)</td>
<td>†</td>
<td>†</td>
</tr>
</tbody>
</table>

*National Physician Survey 2010, The College of Family Physicians of Canada, Canadian Medical Association and Royal College of Physicians and Surgeons of Canada
† Comparable datum not available from National Physician Survey 2010 because it was either not collected, definitions differ from current study or not reported
**Participants within column may not sum to N due to missing values
††SD stands for standard deviation, IQR for Interquartile range
3.2 Physician Factors and Screening Behaviour

Table 3-2 presents the results for physician factors and compares Screeners and Non-Screeners (Questionnaire Section IV). A statistically significant difference was found where Screeners worked more hours per week than Non-Screeners. Differences were marginally significant for practice location; Screeners were more likely to be from rural practices (56%) versus Non-Screeners (29%). There were no statistically significant differences for the remaining variables.
<table>
<thead>
<tr>
<th>Physician Factors</th>
<th>All participants (N = 49)†</th>
<th>Screening practices, n (%)* Screeners (n = 34)</th>
<th>Non-Screeners (n = 15‡)</th>
<th>p-value§</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sex, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>25 (52)</td>
<td>18 (53)</td>
<td>7 (50)</td>
<td>0.85</td>
</tr>
<tr>
<td>Female</td>
<td>23 (48)</td>
<td>16 (47)</td>
<td>7 (50)</td>
<td></td>
</tr>
<tr>
<td><strong>Age, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;50 years</td>
<td>32 (67)</td>
<td>25 (74)</td>
<td>7 (50)</td>
<td>0.18**</td>
</tr>
<tr>
<td>≥50 years</td>
<td>16 (33)</td>
<td>9 (27)</td>
<td>7 (50)</td>
<td></td>
</tr>
<tr>
<td><strong>CCFP certification, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>24 (50)</td>
<td>16 (47)</td>
<td>8 (57)</td>
<td>0.53</td>
</tr>
<tr>
<td>No</td>
<td>24 (50)</td>
<td>18 (53)</td>
<td>6 (43)</td>
<td></td>
</tr>
<tr>
<td><strong>CFPC membership, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>44 (92)</td>
<td>30 (88)</td>
<td>14 (100)</td>
<td>0.31**</td>
</tr>
<tr>
<td>No</td>
<td>4 (8)</td>
<td>4 (12)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td><strong>Group practice, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>38 (81)</td>
<td>26 (77)</td>
<td>12 (92)</td>
<td>0.41**</td>
</tr>
<tr>
<td>No</td>
<td>9 (19)</td>
<td>8 (24)</td>
<td>1 (8)</td>
<td></td>
</tr>
<tr>
<td><strong>Teaching affiliation, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>21 (44)</td>
<td>13 (38)</td>
<td>8 (57)</td>
<td>0.23</td>
</tr>
<tr>
<td>No</td>
<td>27 (56)</td>
<td>21 (62)</td>
<td>6 (43)</td>
<td></td>
</tr>
<tr>
<td><strong>Practice location, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urban</td>
<td>25 (52)</td>
<td>15 (44)</td>
<td>10 (71)</td>
<td>0.09</td>
</tr>
<tr>
<td>Rural/regional</td>
<td>23 (48)</td>
<td>19 (56)</td>
<td>4 (29)</td>
<td></td>
</tr>
<tr>
<td><strong>Number of practice</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>hours/week,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>30.8 (13.8)</td>
<td>34.9 (10.6)</td>
<td>21.0 (16.1)</td>
<td>0.006</td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>35 (24, 40)</td>
<td>36 (27.3, 40)</td>
<td>16.5 (8.3, 36.3)</td>
<td></td>
</tr>
<tr>
<td><strong>Number of years in practice</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>13.9 (12.2)</td>
<td>13.5 (11.6)</td>
<td>14.8 (14.1)</td>
<td>0.95</td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>30.8 (13.8)</td>
<td>10.5 (3.8, 20)</td>
<td>7 (3.3, 30.3)</td>
<td></td>
</tr>
</tbody>
</table>

*Denominator is the number of participants responding to the question
† Totals within columns do not sum to n due to missing values.
§ p-values comparing Screeners and Non-Screeners’ screening practices for categorical variables assessed by Chi square test with **Fisher’s exact test where indicated. Medians for continuous variables compared by Mann-Whitney-U testing.
3.3 Physician Attitudes & Practices by Screening Group

Table 3-3 compares FPs’ lung cancer screening attitudes and practices by screening group (Questionnaire Section II, questions 3-13). Participants’ agreement with statements listed in the table, was dichotomized as yes or no responses. The following discussion of important findings makes brief mention of the corresponding statements; please refer to the table for the full statement text.

A significantly larger proportion of Screeners (85%) than Non-Screeners (50%) agreed with the statement that missing a case of lung cancer would result in increased screening for some time afterwards.

Similarly, a significantly larger proportion of Screeners (67%) than Non-Screeners (21%) agreed with the statement that they would routinely screen if there was a positive family history of lung cancer.

A significantly larger proportion of Screeners (88%) than Non-Screeners (57%) agreed with the statement that they would routinely screen if there was occupational exposure such as asbestos, silica and chemicals.

A significantly larger proportion of Screeners (79%) than Non-Screeners (29%) agreed with the statement that they would routinely screen if there were co-morbid conditions such as COPD.

A significant minority of Screeners (13%) and a majority of Non-Screeners (79%) agreed with the statement that they would not recommend CXR for screening because they thought there was potential to cause more harm than good.

Medico-legal considerations had no impact on screening behaviour among FPs in either group.

Both Screeners and Non-Screeners were equally likely to apply lung cancer guidelines to each individual patient’s needs.
<table>
<thead>
<tr>
<th>Statement</th>
<th>Screeners n = 34</th>
<th>Agreement</th>
<th>Non-Screeners n = 15</th>
<th>p-value†</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yes n (%)*</td>
<td>No n (%)*</td>
<td>Yes n (%)*</td>
<td>No n (%)*</td>
</tr>
<tr>
<td>The guidelines for lung cancer screening are just guidelines.</td>
<td>27 (82)</td>
<td>6 (18)</td>
<td>14 (100)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>I apply lung cancer screening guidelines to each individual patient's needs.</td>
<td>25 (76)</td>
<td>8 (24)</td>
<td>11 (79)</td>
<td>3 (21)</td>
</tr>
<tr>
<td>I tend to follow lung cancer screening guidelines when they are published by an organization that I trust.</td>
<td>31 (94)</td>
<td>2 (6)</td>
<td>12 (86)</td>
<td>2 (14)</td>
</tr>
<tr>
<td>If I missed a case of lung cancer I would tend to screen more patients for that particular disease for some time afterwards.</td>
<td>28 (85)</td>
<td>5 (15)</td>
<td>7 (50)</td>
<td>7 (50)</td>
</tr>
<tr>
<td>I will routinely recommend a lung cancer screening test when there is insufficient evidence, in order to avoid medical-legal repercussions.</td>
<td>7 (21)</td>
<td>26 (79)</td>
<td>2 (15)</td>
<td>11 (85)</td>
</tr>
<tr>
<td>I will routinely recommend a lung cancer screening test for patients if there is a positive family history of lung cancer</td>
<td>22 (67)</td>
<td>11 (33)</td>
<td>3 (21)</td>
<td>11 (79)</td>
</tr>
<tr>
<td>I will routinely recommend a lung cancer screening test for asymptomatic patients when there is a history of occupational exposure to asbestos, silica, or other chemicals.</td>
<td>29 (88)</td>
<td>4 (12)</td>
<td>8 (57)</td>
<td>6 (43)</td>
</tr>
<tr>
<td>Statement</td>
<td>Screeners n = 34</td>
<td>Non-Screeners n = 15</td>
<td>p-value†</td>
<td></td>
</tr>
<tr>
<td>--------------------------------------------------------------------------</td>
<td>------------------</td>
<td>----------------------</td>
<td>----------</td>
<td></td>
</tr>
<tr>
<td>I will routinely recommend a lung cancer screening test when patients have co-morbid conditions such as COPD.</td>
<td>26 (79)</td>
<td>4 (29)</td>
<td>0.002</td>
<td></td>
</tr>
<tr>
<td>I do not recommend CXR for lung cancer screening because I think it has the potential to cause more harm than good.</td>
<td>4 (13)</td>
<td>11 (79)</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td>I do not recommend CT Chest for lung cancer screening because I think it has the potential to cause more harm than good.</td>
<td>20 (63)</td>
<td>10 (71)</td>
<td>0.74</td>
<td></td>
</tr>
</tbody>
</table>

*Denominator is the number of participants responding to the question.
† p-values comparing Screeners and Non-Screeners screening practices for categorical variables assessed by Fisher’s exact test due to frequent small expected cell sizes. Number of responses to a specific statement within the groups may not sum to group total due to missing values. Percentages may sum to more than 100% due to rounding.
3.4 Physicians’ Perceptions of Lung Cancer Screening Guidelines

Table 3-4 reports FPs’ perceptions of lung cancer screening guidelines (Questionnaire Section I). There was a statistically significant difference in that Screeners were more likely (52%) than Non-Screeners (7%) to perceive that CXR was recommended for their smoking patients. There were no statistically significant differences for the remaining variables. Of note, Screeners (69%) and Non-Screeners (46%) found the guidelines for lung cancer screening for asymptomatic smokers to be unclear.
<table>
<thead>
<tr>
<th>Guideline Perception</th>
<th>by test</th>
<th>All (N=49**)</th>
<th>Screeners (n=34**)</th>
<th>Non-Screeners (n=15**)</th>
<th>p-value†</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>For never-smokers</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CXR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recommended, n (%)‡</td>
<td></td>
<td>6 (12)</td>
<td>6 (18)</td>
<td>0 (0)</td>
<td>0.16</td>
</tr>
<tr>
<td>Not recommended§, n (%)</td>
<td></td>
<td>43 (88)</td>
<td>28 (82)</td>
<td>15 (100)</td>
<td></td>
</tr>
<tr>
<td>CT scan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recommended, n (%)</td>
<td></td>
<td>2 (4)</td>
<td>2 (6)</td>
<td>0 (0)</td>
<td>1.0</td>
</tr>
<tr>
<td>Not recommended, n (%)</td>
<td></td>
<td>47 (96)</td>
<td>32 (94)</td>
<td>15 (100)</td>
<td></td>
</tr>
<tr>
<td>Sputum cytology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recommended, n (%)</td>
<td></td>
<td>4 (8)</td>
<td>3 (9)</td>
<td>1 (7)</td>
<td>1.0</td>
</tr>
<tr>
<td>Not recommended, n (%)</td>
<td></td>
<td>45 (92)</td>
<td>31 (91)</td>
<td>14 (93)</td>
<td></td>
</tr>
<tr>
<td><strong>For ever-smokers</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CXR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recommended, n (%)‡</td>
<td></td>
<td>18 (38)</td>
<td>17 (52)</td>
<td>1 (7)</td>
<td>0.003</td>
</tr>
<tr>
<td>Not recommended, n (%)</td>
<td></td>
<td>30 (62)</td>
<td>16 (49)</td>
<td>14 (93)</td>
<td></td>
</tr>
<tr>
<td>CT scan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recommended, n (%)</td>
<td></td>
<td>7 (15)</td>
<td>6 (18)</td>
<td>1 (7)</td>
<td>0.41</td>
</tr>
<tr>
<td>Not recommended, n (%)</td>
<td></td>
<td>41 (85)</td>
<td>27 (82)</td>
<td>14 (93)</td>
<td></td>
</tr>
<tr>
<td>Sputum cytology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recommended, n (%)</td>
<td></td>
<td>9 (18)</td>
<td>8 (24)</td>
<td>1 (7)</td>
<td>0.24</td>
</tr>
<tr>
<td>Not recommended, n (%)</td>
<td></td>
<td>40 (82)</td>
<td>26 (77)</td>
<td>14 (93)</td>
<td></td>
</tr>
<tr>
<td>Clear guidelines for ever-smoking patients, n (%)</td>
<td></td>
<td>17 (38)</td>
<td>10 (31)</td>
<td>7 (54)</td>
<td>0.19</td>
</tr>
<tr>
<td>Yes, n (%)</td>
<td></td>
<td>28 (62)</td>
<td>22 (69)</td>
<td>6 (46)</td>
<td></td>
</tr>
</tbody>
</table>

†p-value comparing Screeners and Non-Screeners screening practices assessed by Fisher’s exact test due to frequent small expected cell sizes.
‡Denominator for all percentages is the number of participants responding to the question
§Not recommended responses to all questions include “recommended against”, “insufficient evidence” and “conflicting guidance”
**Participants within columns may not sum to N or n due to missing values
3.5 Choice of Screening Test among Screeners by patient’s smoking status

Table 3-5 reports the choice of screening tests (Questionnaire Section II, questions 1 b and 2 b) among Screeners. Since the criterion for Screeners and Non-Screeners was based on whether or not FPs screen asymptomatic, ever-smoking patients, FPs in the Screener group will all indicate that they screen these patients while Non-Screeners by definition will not have screened, and, unsurprisingly, all of them indicated that they would not screen never-smokers either. Among Screeners, 16 of the 34 FPs (47%) also screened never-smokers. So although Screeners are more likely to indicate at least some degree of screening among never-smokers compared to Non-Screeners, the data suggest that this tendency is still considerably less than when evaluating ever-smokers (100%). Among Screeners, CXR was the most frequently ordered test (97%) for ever smoking patients and (94%) for never smoking patients.

Table 3-5 Choice of Screening Test by Smoking Status among Screeners (n=34)

<table>
<thead>
<tr>
<th>Screening Test</th>
<th>Never-smokers (Section II Q 1 b)</th>
<th>Ever-smokers (Section II Q 2 b)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CXR, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>15 (94)</td>
<td>33 (97)</td>
</tr>
<tr>
<td>No</td>
<td>1 (6)</td>
<td>1 (3)</td>
</tr>
<tr>
<td>Would not screen</td>
<td>18*</td>
<td></td>
</tr>
<tr>
<td>CT, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>0 (0)</td>
<td>2 (6)</td>
</tr>
<tr>
<td>No</td>
<td>16 (100)</td>
<td>32 (94)</td>
</tr>
<tr>
<td>Would not screen</td>
<td>18*</td>
<td></td>
</tr>
<tr>
<td>Sputum, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>5 (31)</td>
<td>8 (24)</td>
</tr>
<tr>
<td>No</td>
<td>11 (69)</td>
<td>26 (77)</td>
</tr>
<tr>
<td>Would not screen</td>
<td>18*</td>
<td></td>
</tr>
</tbody>
</table>

*Out of 34 Screeners (FPs who will order screening test in ever-smoking patients) 18 did not report ordering screening tests in never-smoking patients
3.6 Influence of Non-medical Factors on Screening Behaviour

Table 3-6 reports the influence of non-medical factors on screening behaviour (Questionnaire Section II, questions 14a-14h). Results were not statistically different for the variables but approached marginal significance in their screening behaviour if the test was easily accessible or if the test was easy to administer. *Screeners* more frequently order screening tests (77%) than *Non-Screeners* (50%).

Table 3-6 Physician agreement that non-medical factors would influence test ordering behaviour

<table>
<thead>
<tr>
<th>Statement</th>
<th>Screeners n = 34</th>
<th>Non-Screeners n = 15</th>
<th>p-value†</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yes n (%)</td>
<td>No n (%)</td>
<td>Yes n (%)</td>
</tr>
<tr>
<td>A patient is anxious about having the disease</td>
<td>29 (85)</td>
<td>5 (15)</td>
<td>9 (69)</td>
</tr>
<tr>
<td>A patient requests the test and insists on having it done</td>
<td>32 (94)</td>
<td>2 (6)</td>
<td>12 (86)</td>
</tr>
<tr>
<td>I hear that my colleagues are recommending it to their patients</td>
<td>9 (27)</td>
<td>25 (74)</td>
<td>2 (14)</td>
</tr>
<tr>
<td>Specialists I work with recommend ordering the test</td>
<td>26 (77)</td>
<td>8 (24)</td>
<td>12 (92)</td>
</tr>
<tr>
<td>The test is inexpensive</td>
<td>21 (62)</td>
<td>13 (38)</td>
<td>6 (43)</td>
</tr>
<tr>
<td>The test is easily accessible</td>
<td>26 (77)</td>
<td>8 (24)</td>
<td>7 (50)</td>
</tr>
<tr>
<td>The test is easy to administer</td>
<td>26 (77)</td>
<td>8 (24)</td>
<td>7 (50)</td>
</tr>
<tr>
<td>The test will take less time to order than to convince a patient they do not need it</td>
<td>14 (41)</td>
<td>20 (59)</td>
<td>5 (36)</td>
</tr>
</tbody>
</table>

†p-values comparing *Screeners* and *Non-Screeners’* screening practices for categorical variables assessed by Fisher’s exact test due to frequent small expected cell sizes. Number of responses to a specific statement within the groups may not sum to group total due to missing values. Percentages may sum to more than 100% due to rounding.
3.7 Influence of Lung Cancer in Self or Close Relative and Smoking on Screening Behaviour

Table 3-7 reports the influence of a lung cancer diagnosis for physician personally or for someone close or of smoking status on screening behaviour (Questionnaire Section V, questions 1-3).

There were no statistically significant differences between Screeners and Non-Screeners in the proportion who had experienced a diagnosis of lung cancer themselves or anyone close to them. This response could not be further assessed by smoking status since 29 out of 51 participants answered both questions as smoker and as non-smoker and as such could not be clearly assigned as either smoker or non-smoker.

**Table 3-7 Close experience with lung cancer and smoking status**

<table>
<thead>
<tr>
<th></th>
<th>All participants N = 49</th>
<th>Screeners n = 34†</th>
<th>Non-Screeners n = 15†</th>
<th>p-value‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>Have you or anyone close to you ever been diagnosed with lung cancer? n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>13 (27)</td>
<td>11 (32)</td>
<td>2 (14)</td>
<td>0.29</td>
</tr>
<tr>
<td>No</td>
<td>35 (73)</td>
<td>23 (68)</td>
<td>12 (86)</td>
<td></td>
</tr>
<tr>
<td>Would seek screening for self, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>5 (11)</td>
<td>5 (15)</td>
<td>0 (0)</td>
<td>0.30</td>
</tr>
<tr>
<td>No</td>
<td>41 (89)</td>
<td>28 (85)</td>
<td>13 (100)</td>
<td></td>
</tr>
</tbody>
</table>

†Participants within columns may not sum to n due to missing values.
‡Fisher’s exact test
3.8 Influence of Patient Factors in Clinical Vignettes

Table 3-8 reports the proportion of participants who indicated they would screen for each of the six scenarios (Questionnaire Section III). CXR was the most frequently ordered test.

Table 3-8 Proportions of participants screening using CXR, CT, or sputum cytology in uncomplicated and complicated scenarios

<table>
<thead>
<tr>
<th></th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CXR</strong></td>
<td></td>
</tr>
<tr>
<td>Uncomplicated Scenario</td>
<td></td>
</tr>
<tr>
<td>No complications</td>
<td>23 (48%)</td>
</tr>
<tr>
<td>Complicating dynamic</td>
<td></td>
</tr>
<tr>
<td>Expectation</td>
<td>21 (44%)</td>
</tr>
<tr>
<td>Anxiety</td>
<td>28 (58%)</td>
</tr>
<tr>
<td>Family History</td>
<td>30 (63%)</td>
</tr>
<tr>
<td>Poor relationship</td>
<td>23 (48%)</td>
</tr>
<tr>
<td>All four dynamics</td>
<td>35 (73%)</td>
</tr>
<tr>
<td><strong>CT Chest</strong></td>
<td></td>
</tr>
<tr>
<td>Uncomplicated Scenario</td>
<td></td>
</tr>
<tr>
<td>No complications</td>
<td>3 (6%)</td>
</tr>
<tr>
<td>Complicating dynamic</td>
<td></td>
</tr>
<tr>
<td>Expectation</td>
<td>2 (4%)</td>
</tr>
<tr>
<td>Anxiety</td>
<td>3 (6%)</td>
</tr>
<tr>
<td>Family History</td>
<td>3 (6%)</td>
</tr>
<tr>
<td>Poor relationship</td>
<td>2 (4%)</td>
</tr>
<tr>
<td>All four dynamics</td>
<td>8 (17%)</td>
</tr>
<tr>
<td><strong>Sputum cytology</strong></td>
<td></td>
</tr>
<tr>
<td>Uncomplicated Scenario</td>
<td></td>
</tr>
<tr>
<td>No complications</td>
<td>9 (19%)</td>
</tr>
<tr>
<td>Complicating dynamic</td>
<td></td>
</tr>
<tr>
<td>Expectation</td>
<td>6 (13%)</td>
</tr>
<tr>
<td>Anxiety</td>
<td>5 (10%)</td>
</tr>
<tr>
<td>Family History</td>
<td>7 (15%)</td>
</tr>
<tr>
<td>Poor relationship</td>
<td>6 (13%)</td>
</tr>
<tr>
<td>All four dynamics</td>
<td>8 (17%)</td>
</tr>
</tbody>
</table>
3.9 Influence of Patient Factors in Clinical Vignettes

Table 3-9 compares the proportion of participants who screened in the uncomplicated scenario (Scenario 1) with each of the complicated scenarios (Scenario 2 – 6). The purpose of the analysis is to determine if the factor(s) introduced in each scenario significantly affects the decision to order each lung cancer screening test. The p-value shown indicates if there is a statistically significant effect due to the introduction of this factor. It is computed using the McNemar test for matched pairs of data, in this case the comparison of results for the uncomplicated scenario with each of the complicated scenarios. Note that participants are not divided into the previous Screener/Non-Screener categories. The table divides participants into two groups, those who screened in the uncomplicated scenario and those who did not. Within each group, results are further subdivided into those who would/would not screen to make it easier to see changes in behaviour between the scenarios and groups.

A walkthrough will be presented to make this clearer. The first set of yes and no values indicate that 23 participants said they would screen using a CXR in the uncomplicated scenario (Scenario 1), while 25 participants said they would not. So based on this response, the respondents were divided in two groups; Uncomplicated Screeners and Uncomplicated Non-Screeners.

We then looked at the responses of Uncomplicated Screeners to see what they would do in complicated scenarios. We found that if the patient expects the test, 15 of the 23 (65%) that did screen in Scenario 1 would also screen when the complicating dynamic expectation was added (Scenario 2), while 8 (35%) would not.

Similarly, among the 25 participants who indicated they would not screen in the uncomplicated situation, 6 (24%) now would screen when the patient expects the test as in Scenario 2. However, 19 participants (76%), did not change their position and would not screen whether the patient expected the test or not.
So the question is, does adding the dynamic of expectation to the patient-physician interaction change the proportion of participants who would screen? To assess this, our interest is in those who change their screening decisions between the two scenarios. On the left hand side we see that, when we add the element of expectation (Scenario 2), 8 of the 23 participants (35%) who would have screened in Scenario 1 choose not to screen with a CXR in Scenario 2, while 6 of the 25 participants who would not have screened in Scenario 1 (right side), choose to screen in Scenario 2. The McNemar statistic examines the difference in the choices made in each of these scenarios. In case of Scenario 2 versus Scenario 1, there is no statistically significant change in choices (p-value=0.79. As such we can draw no overall conclusion about the impact of patient expectation on screening decisions – in some it appears to decrease the tendency to screen, while in others it seems to increase it.

Similarly, the results do not show a statistically significant change with the addition of complicating dynamics of anxiety, family history or poor relationship are added as individual complicating dynamics in each of the scenarios. We do however, find the results to be clinically relevant as 40% participants who did not screen in Scenario 1 indicated they will screen if positive family history was added (Scenario 4).

Results show a statistically significant difference for participants’ responses in the uncomplicated scenario (Scenario 1) compared to responses for the multiple dynamic scenario (Scenario 6) p-value=0.006.

There is no statistically significant indication that FPs will change their screening practices with chest CT or sputum cytology when the dynamics of patient expectation, patient anxiety, family history, or poor patient-physician relationship are present compared to when they are not. Overall it appears that FPs are generally unlikely to screen ever-smokers with chest CT under any scenario situations.
Table 3-9 Comparison of the proportions of participants screening using CXR, CT, or sputum cytology in uncomplicated versus complicated patient-physician interactions

<table>
<thead>
<tr>
<th>Complicating dynamic</th>
<th>Screen in uncomplicated scenario</th>
<th>Screen in complicated scenario</th>
<th>p-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yes, n = 23 (48%)</td>
<td>No, n = 25 (52%)</td>
<td></td>
</tr>
<tr>
<td>CXR</td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Expectation</td>
<td>15 (65%)</td>
<td>8 (35%)</td>
<td>6 (24%)</td>
</tr>
<tr>
<td>Anxiety</td>
<td>21 (91%)</td>
<td>2 (9%)</td>
<td>7 (28%)</td>
</tr>
<tr>
<td>Family History</td>
<td>20 (87%)</td>
<td>3 (13%)</td>
<td>10 (40%)</td>
</tr>
<tr>
<td>Poor relationship</td>
<td>18 (78%)</td>
<td>5 (22%)</td>
<td>5 (20%)</td>
</tr>
<tr>
<td>All four dynamics</td>
<td>21 (91%)</td>
<td>2 (9%)</td>
<td>14 (56%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Complicating dynamic</th>
<th>Screen in uncomplicated scenario</th>
<th>Screen in complicated scenario</th>
<th>p-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yes, n = 3 (6%)</td>
<td>No, n = 45 (94%)</td>
<td></td>
</tr>
<tr>
<td>CT Chest</td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Expectation</td>
<td>1 (33%)</td>
<td>2 (67%)</td>
<td>1 (2%)</td>
</tr>
<tr>
<td>Anxiety</td>
<td>2 (67%)</td>
<td>1 (33%)</td>
<td>1 (2%)</td>
</tr>
<tr>
<td>Family History</td>
<td>2 (67%)</td>
<td>1 (33%)</td>
<td>1 (2%)</td>
</tr>
<tr>
<td>Poor relationship</td>
<td>1 (33%)</td>
<td>2 (67%)</td>
<td>1 (2%)</td>
</tr>
<tr>
<td>All four dynamics</td>
<td>1 (33%)</td>
<td>2 (67%)</td>
<td>7 (16%)</td>
</tr>
<tr>
<td>Complicating dynamic</td>
<td>Screen in uncomplicated scenario</td>
<td>Screen in complicated scenario</td>
<td></td>
</tr>
<tr>
<td>----------------------</td>
<td>---------------------------------</td>
<td>--------------------------------</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Yes, n = 9 (19%)</td>
<td>No, n = 39 (81%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>5 (56%)</td>
<td>4 (44%)</td>
<td></td>
</tr>
<tr>
<td>Expectation</td>
<td>1 (3%)</td>
<td>38 (97%)</td>
<td></td>
</tr>
<tr>
<td>Anxiety</td>
<td>5 (56%)</td>
<td>4 (44%)</td>
<td></td>
</tr>
<tr>
<td>Family History</td>
<td>0 (0%)</td>
<td>39 (100%)</td>
<td></td>
</tr>
<tr>
<td>Poor relationship</td>
<td>4 (44%)</td>
<td>5 (56%)</td>
<td></td>
</tr>
<tr>
<td>All four dynamics</td>
<td>7 (78%)</td>
<td>2 (22%)</td>
<td></td>
</tr>
</tbody>
</table>

*p-value* = McNemar’s test comparing the proportion of participants who would screen in the uncomplicated scenario to the proportion screening in each of the complicated scenarios.
3.10 Proportion of participants screening within each scenario by perception of screening recommendation

Table 3-10 reports on the influence of perception of screening guideline recommendations on screening decision making. For this analysis, the significant p-value was set at 0.008 to account for multiple testing. In scenarios where the patient-physician interaction was uncomplicated, patients expected the test, or patients had a family history of disease, participants were statistically significantly more likely to screen with a CXR if they perceived that it was recommended than if it was not. Recommendations did not clearly change screening practice if the patient was anxious, had a difficult relationship with the physician, or had multiple dynamics, as participants who did not perceive the test as recommended often showed some tendency to screen under these conditions.

From the group of FPs who did not perceive CXR was recommended and did not screen (21), a clinically significant number of them were influenced to screen if the patient was anxious or there was a positive family history of disease (for each factor, an increase from 8 to 13 out of 21, 63%) and with multiple dynamics (an increase from 8 to 19 out of 21, 138%).

So we can conclude that perception of recommendations influences FPs decision-making for lung cancer screening with CXR. However, when faced with patient factors of anxiety, difficult relationship and multiple complicating factors FPs decision to screen over-rides their perception meaning that these factors influence their decision-making.

Perception of recommendation regarding screening with CT did not appear to make a difference as to whether participants would screen or not. Although 7 individuals indicated that they felt CT is recommended as a screening tool in ever-smokers, its use was infrequently indicated in the scenarios.

Perception of recommendation regarding screening with sputum cytology appeared to make a difference in all scenarios as to whether or not a FP decided to screen. In each scenario approximately half to two-thirds of the nine FPs who felt that screening with
cytology in ever-smokers is recommended indicated that they would screen, while less than 10% of those who felt that cytological screening was not recommended, indicated they would order it. This contrast was statistically significant in all comparisons regardless of the presenting dynamic.
<table>
<thead>
<tr>
<th></th>
<th>Overall N=48*</th>
<th>Perceived as recommended, n=18</th>
<th>Not perceived as recommended, n=29</th>
<th>p-value†</th>
</tr>
</thead>
<tbody>
<tr>
<td>CXR</td>
<td></td>
<td>Screen, n (%)</td>
<td>Screen, n (%)</td>
<td>Screen, n (%)</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Uncomplicated</td>
<td>23 (48)</td>
<td>25 (52)</td>
<td>14 (78)</td>
<td>4 (22)</td>
</tr>
<tr>
<td>Expectation</td>
<td>21 (43)</td>
<td>27 (57)</td>
<td>14 (78)</td>
<td>4 (22)</td>
</tr>
<tr>
<td>Anxiety</td>
<td>28 (58)</td>
<td>20 (42)</td>
<td>14 (78)</td>
<td>4 (22)</td>
</tr>
<tr>
<td>Family history</td>
<td>30 (62)</td>
<td>18 (38)</td>
<td>16 (89)</td>
<td>2 (11)</td>
</tr>
<tr>
<td>Poor relationship</td>
<td>23 (48)</td>
<td>25 (52)</td>
<td>12 (67)</td>
<td>6 (33)</td>
</tr>
<tr>
<td>All four dynamics</td>
<td>35 (73)</td>
<td>13 (27)</td>
<td>15 (83)</td>
<td>3 (17)</td>
</tr>
</tbody>
</table>

<p>| Chest CT       | Overall N = 48* | Perceived as recommended, n=7 | Not perceived as recommended, n=40† | p-value |
|                | Yes  | No | Yes  | No | Yes  | No | Yes  | No |
| Uncomplicated  | 3 (6) | 45 (94) | 1 (14) | 6 (86) | 2 (5) | 38 (95) | 0.39 |
| Expectation    | 2 (4) | 46 (96) | 0 (0)  | 7 (100) | 2 (5) | 38 (95) | 1.0  |
| Anxiety        | 3 (6) | 45 (94) | 1 (14) | 6 (86) | 2 (5) | 38 (95) | 0.39 |
| Family history | 3 (6) | 45 (94) | 1 (14) | 6 (86) | 2 (5) | 38 (95) | 0.39 |
| Poor relationship | 2 (4) | 46 (96) | 1 (14) | 6 (86) | 1 (3)  | 39 (97) | 0.28 |
| All four dynamics | 8 (17) | 40 (83) | 2 (29)  | 5 (71)  | 6 (15) | 34 (85) | 0.59 |</p>
<table>
<thead>
<tr>
<th>Sputum cytology</th>
<th>Overall N = 48*</th>
<th>Perceived as recommended, n=9</th>
<th>Not perceived as recommended, n=39</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Screen, n (%)</td>
<td>Screen, n (%)</td>
<td>Screen, n (%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Uncomplicated</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>9 (19)</td>
<td>39 (81)</td>
<td>6 (67)</td>
<td>3 (33)</td>
</tr>
<tr>
<td>Expectation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>6 (12)</td>
<td>42 (88)</td>
<td>5 (56)</td>
<td>4 (44)</td>
</tr>
<tr>
<td>Anxiety</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>5 (10)</td>
<td>43 (90)</td>
<td>4 (44)</td>
<td>5 (56)</td>
</tr>
<tr>
<td>Family history</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>7 (15)</td>
<td>41 (85)</td>
<td>5 (56)</td>
<td>4 (44)</td>
</tr>
<tr>
<td>Poor relationship</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>6 (12)</td>
<td>42 (88)</td>
<td>6 (67)</td>
<td>3 (33)</td>
</tr>
<tr>
<td>All four dynamics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>8 (17)</td>
<td>40 (83)</td>
<td>6 (67)</td>
<td>3 (33)</td>
</tr>
</tbody>
</table>

*One participant did not provide a response to the vignette questions; among the remaining 48, two did not state their perception of CXR and CT respectively in ever-smokers;

†p-values from Fisher’s exact test due to frequent small expected cells sizes and α = 0.008 to compensate for multiple comparisons (0.05/6 scenarios).
3.11 Conclusions

Results showed a substantial variation in reported lung cancer screening behaviour among FPs. Participants were classified as Screeners (69%) or Non-Screeners (31%) based on whether or not they reported ordering screening tests for their asymptomatic ever-smoker patients. Among Screeners, 16 of the 34 FPs (47%) also screened never-smokers.

Screeners were more likely to work more hours per week than Non-Screeners but were otherwise not distinguishable with respect to gender, age, College Certification or membership, type of practice, practice location or teaching affiliation.

Despite the fact that national guidelines did not recommend CXR as a screening test, it was the most frequently ordered test.

Missing a case of lung cancer resulted in increased screening behaviour for some time afterwards in both Screeners (85%) and Non-Screeners (50%). Similarly, a positive family history of lung cancer, occupational exposure such as asbestos, silica and chemicals or presence of comorbid conditions such as COPD resulted in a statistically significant difference in screening behaviour in Screeners (67%) and Non-Screeners (21%).

A minority of Screeners (13%) and a majority of Non-Screeners (79%) did not recommend CXR for screening because they thought there was potential to cause more harm than good. Medico-legal considerations had no impact on screening behaviour among FPs in either group.

Both Screeners and Non-Screeners were equally likely to apply lung cancer screening guidelines to each individual patient’s context.

Screening behaviour was influenced in favour of screening if the test was easily accessible or if the test was easy to administer, Screeners (77%) and Non-Screeners (50%).
Thirty-nine percent of FPs perceived CXR was recommended for lung cancer screening even though the prevailing guidelines at the time of data collection did not recommend CXR as a lung cancer screening test. It is interesting to note that both Screeners and Non-Screeners found the guidelines for lung cancer screening for asymptomatic ever smokers to be unclear.

It is worth noting that 18 participants thought CXR was recommended, but when faced with a scenario, 23 actually ordered one. Their responses changed when the question was one about recommended guidelines or a hypothetical case scenario suggesting that patient factors are a major influence on FP screening decision-making behaviour.

The fact that 48% screened in the uncomplicated scenario contrary to prevailing national guidelines, suggests that there must be other factors (besides the complicating dynamics assessed in this study) influencing their decision-making.

Among the participants who would not screen in the uncomplicated scenario, some indicated they will screen in the presence of additional factors (expectation, anxiety, family history, poor relationship) indicating that these factors influence their decision-making.

FPs’ decision making is influenced by their perception of guidelines, however the presence of certain patient factors over rides their perception and influences their decision-making.
Chapter 4
Discussion

4.1 Introduction

This study made several important findings regarding the lung cancer screening practices and decision-making of family physicians (FPs) practicing in urban and rural Saskatchewan. First, the results showed a substantial variation in the reported lung cancer screening behaviour of FPs, both in their decision to screen and choice of screening test, with a majority of participants reporting they screened for lung cancer. Second, chest X-ray (CXR) was the most commonly ordered screening test. Third, based on whether or not they reported ordering screening tests for their asymptomatic ever-smoker patients, 69% were classified as Screeners. Fourth, clinical decision-making was assessed via clinical vignettes; the results demonstrated that up to 73% of FPs would order CXR for screening, contrary to prevailing guidelines. A significant number of FPs indicated they would screen in response to multiple patient factors (expectation, anxiety, family history, poor patient-physician relationship) in contrast to an uncomplicated patient scenario. This was true even for FPs who had indicated in another question that they perceived the guidelines to be against screening.

This study is unique, the first study regarding lung cancer screening in Canada. It contributes to the literature about existing FPs’ practices and decision-making regarding lung cancer screening and highlights implications to health care cost, patient care, CME initiatives, and clinical practice guidelines.

4.2 Physician Factors and Screening Behaviour

Screeners were more likely to work more hours per week than Non-Screeners but were otherwise not distinguishable with respect to sex, age, college certification or membership, type or location of practice, teaching affiliation or number of years of practice. This is similar to what Tudiver et al found,2,53 in that all of the above-mentioned factors did not significantly influence primary care physicians’ (PCPs) screening
decisions for breast, colorectal and prostate cancer. However, recent studies on lung cancer screening by PCPs found increased screening was associated with physicians having more than 10 years in practice in one study\(^9\), and in another more than 20 years\(^{39}\). A larger sample size might demonstrate similarities or differences between Screeners and Non-Screeners, thereby permitting further comparison with the findings of other studies.

### 4.3 Influence of Physician Attitudes on Screening Behaviour

Some statistically significant differences were found between Screeners and Non-Screeners when asked if they would screen in the presence of potentially influential physician or patient factors (one factor per question).

Screeners were more likely to be influenced to screen than Non-Screeners by one physician factor and by three patient factors. Missing a case of lung cancer influenced FPs stated behaviour to increase screening. This result is consistent with the influence of this physician factor in Tudiver’s qualitative study\(^{10}\) for other cancers. Similarly, positive family history, occupational exposure such as asbestos, silica and chemicals, and the presence of comorbid conditions such as COPD resulted in increased screening behaviour. These patient factors consist of known risks for developing lung cancer other than by smoking.\(^7\) The positive influence of these factors on screening can be explained by Screeners using evidence-based decision making for a population at risk (ignoring issues surrounding choice of screening test).

Non-Screeners (79\%) were more likely than Screeners (13\%) to not recommend CXR for screening due to the belief that it had the potential to cause more harm than good. The strong influence for Non-Screeners is consistent with evidence-based decision making informed by risk of potential harm.\(^7\) This physician factor is consistent with its identification by Tudiver\(^{10}\). However, it was found to have a relatively weak screening influence for screening using PSA and mammograms in Tudivers’ survey.\(^{53}\)
4.4 Physicians’ Perception of Lung Cancer Screening Guidelines

Screeners were more likely (52%) than Non-Screeners (7%) to perceive that CXR was recommended for their smoker patients. Yet, there are no guidelines, which recommend use of CXR as screening test under any patient conditions. It is interesting to note that both Screeners (69%) and Non-Screeners (46%) found the guidelines for lung cancer screening for asymptomatic ever smokers to be unclear. The results of this study demonstrate wide variation in lung cancer screening practices between FPs and frequent ordering of tests not recommended in national guidelines. It is important to address this variation as well as other guideline discordant practices as they have significant, unnecessary clinical and cost implications. As an example, guideline discordant care for lung cancer in elderly patients results in poor survival outcomes. Unnecessary tests may cause avoidable radiation exposure and anxiety that may be induced by false positive results.

In part, these results imply a gap in knowledge with respect to lung cancer screening guidelines. The survey item which collected these data directly measured perception, not knowledge. It was not possible to know in advance which of potentially many guideline(s) the respondent was informed by, so direct questioning about knowledge of a specific guideline or guidelines would be premature and outside the scope of the study. Asking about perception also avoided potential risk of non-response if a participant felt he/she was being tested/assessed on specific guideline knowledge. None the less, even though the survey item measured perception, it also indirectly measured knowledge, finding some knowledge gaps with respect to related parts of a specific guideline. This was true for the perception that guidelines recommended CXR for smoker patients, when no major guidelines did so. This finding highlights one significant gap, but are there others? More comprehensive research, measuring detailed knowledge of specific guidelines would be valuable and necessary to find all the gaps. They could then be addressed by revised guidelines, arranging CME training, or publishing guidelines in journals. To allow access and wider dissemination, guidelines for lung cancer screening can be made part of the electronic medical record (EMR).
Future research should explore why FPs order CXR as a screening test, especially among those who perceived guidelines did not recommend using CXR as a lung cancer screening test. This could be achieved by conducting qualitative research, either in-depth interviews or focus groups.

Both Screeners and Non-Screeners were equally likely to state that they apply lung cancer guidelines to each individual patient’s context consistent with findings in literature.\textsuperscript{73,74}

### 4.5 Choice of Screening Test among Screeners

Screeners comprised 69\% of FPs. Among these Screeners, 47\% also screened never-smokers.

CXR was the most frequently ordered lung cancer screening test, reported by 67\% of FPs, despite the fact that national guidelines did not recommend CXR for this purpose. This was confirmed by the results from clinical scenarios with multiple dynamics (Scenario 6), where 35 out of 48 FPs (73\%) said they would screen using CXR. This seems to indicate a higher prevalence than reported in a prior U.S. study, which utilized a survey questionnaire to measure attitudes, beliefs and behaviour for lung cancer screening. It concluded that a substantial number of physicians (amongst FPs and pulmonologists) reported they screen for lung cancer using CXR (25\%) despite the fact that it was not recommended.\textsuperscript{9}

The question about why FPs order CXR screening tests remains unanswered. Since a surprisingly large number of participants indicated they screen using CXR in this study, further research to identify the factors that influence decision-making for lung cancer screening should be conducted. A qualitative research design can explore this in future. This knowledge will help to address the frequency of its use as it results in unnecessary investigations and has unnecessary cost implications\textsuperscript{69,70} without any return in improved health care delivery.
4.6 Influence of Non-medical Factors on Screening Behaviour

Screening behaviour was influenced in favour of screening if the test was easily accessible or if the test was easy to administer. This finding did not reach statistical significance but was a clinically relevant difference that in a larger sample may have been significant. This finding may help to shed some light on why FPs did not report ordering a CT scan and sputum cytology at a high frequency. It might be that CXR was the most ordered screening test because of its availability at most rural, regional and urban sites. CXR might also be ordered as a baseline comparison reference, believed to be an inexpensive way to detect potential lung cancer via abnormal changes in subsequent images. CT Scanners are not available in rural facilities and radiologists at regional sites may refuse tests for screening purposes because of staffing issues or may triage as a CT that can be done several months later. It may also be that FPs offer CT chest as a screening test but patients refuse it to avoid driving or because some of them may be dependent on family members living at remote sites. As well, sputum cytology may yield high false negative tests and it may be that FPs consult pulmonologists for bronchoscopy and sputum cytology instead of ordering it themselves.

4.7 Influence of Lung Cancer in Self or Anyone Close and Smoking Status on Screening Behaviour

There were no statistically significant differences between Screeners (32%) and Non-Screeners (14%) based on themselves or close relatives having lung cancer on screening behaviour. These results are consistent with the Tudiver survey which did not report significant influence. Note that this physician factor was represented in the current study population, reported by (27%) participants, with the larger proportion being Screeners. A larger sample size might demonstrate similarities or differences between Screeners and Non-Screeners.
4.8 Influence of Patient Factors in Clinical Scenarios

Section III of the survey consisted of the vignette-based study, which explored participants’ intended behaviour under the influence of patient factors also called complicating scenarios. The outcome was the decision to order one or more types of lung cancer screening tests in each scenario. The goal was to discover the influence of these factors on FPs’ decision-making.

Results for clinical scenarios for the baseline uncomplicated scenario (Scenario 1) showed 48% of participants would order a CXR to screen for lung cancer. The results showed a statistically significant increase in the screening behaviour in the presence of multiple patient factors (Scenario 6 – all four dynamics) p=0.006. When positive family history was added as complicating factor, the results showed a clinically relevant increase in CXR screening behaviour. Only a larger study would determine whether these trends are statistically significant.

On the other hand, non-screeners in the uncomplicated scenario showed a tendency to increase screening in each complicated scenario with statistical significance found when all four dynamics were in play. The non-screeners in the uncomplicated scenario seem to be leaning toward screening when complicating dynamics are added while the screeners in uncomplicated scenario leaned in the opposite direction. Only a larger study would determine whether these trends are statistically significant. If they are, further qualitative research might address the differences in approach to their practice.

There were no statistically significant indications that FPs will change their screening practices with chest CT or sputum cytology when the dynamics of patient expectation, patient anxiety, family history, or poor patient-physician relationship are present compared to when they are not. Overall, it appears that FPs were generally unlikely to screen ever-smokers with chest CT under any scenario. It is interesting to note, however, that only approximately half of the nine participants who would have screened using sputum cytology in the uncomplicated scenario would not do so in more complex situations. Further research might explore the rationale behind this observation.
FPs were more likely to make decisions according to their perception of guidelines as was observed in the responses for the uncomplicated scenario (Scenario 1) and in the presence of patient expectation (Scenario 2) and family history (Scenario 3) for CXR and in all complicating scenarios for sputum cytology. However, the presence of certain patient factors in the simulated clinical scenarios (patient anxiety, poor patient-physician relationship and multiple dynamics) influences their decision-making over-riding their perception of guidelines.

These findings are consistent with the results of Haggerty et al\textsuperscript{2} who found that decision-making by some FPs, who normally followed evidence-based practice (guideline perception) was overridden in the presence of influential patient factors. Decision-making was influenced by patient anxiety or expectation for the cancers they studied (breast, colon and prostate). This study of lung cancer screening decision-making demonstrated this phenomenon for multiple patient factors (patient anxiety, expectation, positive family history, poor patient-physician relationship).

The notion that patient factors may lead FPs to override their decision to follow guidelines is further supported by other findings of this study. When asked in a single-item opinion-based question if CXR is recommended for lung cancer screening, 18 participants responded that they perceived that CXR was recommended; yet, when faced with an uncomplicated patient scenario, 23 indicated they would order a CXR. The fact that 48% screened in the Uncomplicated Scenario contrary to prevailing national guidelines, suggests that there must be other factors (besides the complicating factors assessed in this study) influencing their decision-making. In summary, presence of multiple factors (patient anxiety, expectation, positive family history of lung cancer, poor patient-physician relationship) significantly influenced FPs decisions to screen and over-rides their perception of guidelines. These findings illustrate the influence of patient factors on evidence-based medicine for lung cancer screening decision-making.

Makers of clinical practice guidelines should consider patient context to formulate better guidelines. Recent research promotes incorporating patient preferences and context into the guideline development process and are easy to use for physicians.\textsuperscript{73} Patient
preferences and context are essential to shared decision making. The level of compliance depends on patient involvement and consideration of their specific context highlighting the need to improve the guideline development process. Strong recommendations are discouraged where the best decision depends on patient factors – preferences, context, goals, values.\textsuperscript{75}

The high self-reported prevalence in single item questions and measured inclination to screen in clinical scenarios using CXR needs to be addressed. These findings on lung cancer screening decision-making should be of considerable interest in the current culture of health care cost reduction, for example, the \textit{Choosing Wisely Canada}\textsuperscript{76} campaign encouraging patient-physician dialog about unnecessary tests, treatments and procedures.

\textbf{4.9 Implications}

The study findings on FPs’ lung cancer screening decision-making suggest the following important clinical implications:

1. Ordering of CXRs, which is against evidence-based guidelines adds unnecessary costs and burden on the health care system.

2. Guideline discordant investigations and false positive tests cause anxiety thereby increasing morbidity and further exposure to radiation with more investigations and consultations without any benefit to the patient.

3. Lack of knowledge of guidelines leads to variation in practice, highlighting the need for wide dissemination of evidence-based guidelines by CME, and/or integration within an EMR.

4. Various strategies in guideline development such as incorporating patient preferences, and engagement of patient values and preferences in decision-making may be employed to implement guidelines.\textsuperscript{44,73,74,77-84}

5. The need for guideline makers and those implementing quality improvement strategies that measure adherence to guidelines to recognize that some variability is to be expected.\textsuperscript{73,74}
4.10 Strengths

The study made use of evidence that incorporating a clinical vignettes design is a preferred methodology to assess physician behaviour and decision-making in surveys. Single-item questions responses are subject to recall bias and do not allow behaviour assessment in varying patient-specific contexts which are observed in routine clinical encounters. A clinical vignette methodology allowed simulating real life clinical encounters and permitted studying FP’s intended behaviour in the presence of varied patient factors. Clinical vignettes have been shown to be a valid and cost-effective method to assess physician clinical decision-making, including those in cancer care.\textsuperscript{85-88} Peabody\textsuperscript{85} concluded that clinical case vignettes appear to be a valid and comprehensive method to focus on actual clinical practice in an outpatient setting, rather than physician competence. That study ranked the relative effectiveness of assessing clinical decision-making as 1) standardized patients, 2) clinical case vignettes and 3) chart abstraction. Research, specifically on vignette-based surveys\textsuperscript{88} demonstrated they were more time efficient than record reviews or using standardized patients, and more cost-effective than standardized patients to assess clinical decision-making. Thus, the current survey that included clinical scenarios used the best evidence-based methodology available.

4.11 Limitations

The study has the following known limitations:

1. The ability to generalize to all FPs in Saskatchewan is limited by the low response rate. It is not possible to know if the sample was representative of the screening behaviour of the provincial population of FPs. However, it did appear that FP characteristics in our sample were comparable to provincial and Canadian FPs.

2. The study was limited to FPs in Saskatchewan, so the results may not reflect behaviour of all Canadian FPs.

3. The sample size was small making it difficult to detect clinically relevant differences. Statistical significance may not have been seen for many analyses because the sample size was relatively small and for repeated measures, the
Bonferroni adjustment was a strong correction to the p-value. However, there appeared to be clinically relevant trends and additional significance might be seen with a larger sample size. The proportions are susceptible to changes with small variation in the allocation of participants, again due to small sample size.

4. The results are based on FPs’ reported behaviour and may be subject to desirability bias. Further research might be done to validate self-reported data, for example by comparison with chart audit of medical records.

5. The survey design can explore behaviour but not reasons behind the behaviour. Future qualitative study can address this concern.

### 4.12 Direction for future research

The results of the present study emphasize the need to better understand reported lung cancer screening behaviour and decision-making suggesting four potential research studies.

1. Research to examine why FPs screen patients for lung cancer and why they order CXR as a screening test. This research would examine the factors identified in this study and any additional factors that influence FPs’ lung cancer screening decision-making. This could be achieved by conducting qualitative research, either in-depth interviews or focus groups.

2. After exploring qualitatively the factors influencing FPs’ lung cancer screening, a national Canadian survey of FPs regarding their behaviour and decision-making for lung cancer.

3. Research to assess FPs’ actual lung cancer screening behaviour by chart audit to address desirability bias and recall bias in self-reported behaviour in surveys.

4. Research to explore how guideline makers might engage FPs in the development of guidelines in the context of family practice. The results may then be used to inform guideline makers so that they can address concerns raised by their users.
References


Appendix A
Lung Cancer Screening Survey Instrument
A STUDY OF HOW FAMILY PHYSICIANS MAKE LUNG CANCER SCREENING DECISIONS

THANK YOU FOR COMPLETING THIS QUESTIONNAIRE.

THE DEPARTMENT OF FAMILY MEDICINE,
SCHULICH SCHOOL OF MEDICINE AND DENTISTRY

PLEASE RETURN THE QUESTIONNAIRE IN THE ENCLOSED ENVELOPE TO:
DR N. JAMIL
SECTION I

IN THIS SECTION WE WILL ASK YOU SOME QUESTIONS ABOUT YOUR PERCEPTION OF THE CURRENT GUIDELINES FOR SCREENING ASYMPTOMATIC PATIENTS FOR LUNG CANCER.

In this section “current guidelines” refers to any guidelines that you may have read regardless of the organization or country they were published by.

Please check or circle the response for each question.

1. **What do you perceive the current guidelines for screening for lung cancer say for asymptomatic patients with no risk factors?**

<table>
<thead>
<tr>
<th>Screening Manoeuvre</th>
<th>Recommended</th>
<th>Recommend Against</th>
<th>Insufficient Evidence</th>
<th>Conflicting Guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chest X-ray</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>CT Chest</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Sputum Cytology</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>

2. **What do you perceive the current guidelines for screening for lung cancer say for asymptomatic patients with smoking as a risk factor (i.e. current/past smokers)?**

<table>
<thead>
<tr>
<th>Screening Manoeuvre</th>
<th>Recommended</th>
<th>Recommend Against</th>
<th>Insufficient Evidence</th>
<th>Conflicting Guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chest X-ray</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>CT Chest</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Sputum Cytology</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>

3. **Do you consider the current guidelines for screening for lung cancer for asymptomatic patients with smoking as a risk factor (i.e. current/past smokers) to be clear and non-conflicting (i.e. two or more organizations have similar views)?**

1. Yes
2. No

SURVEY EVALUATION

YOUR COMMENTS ARE APPRECIATED, EITHER HERE OR ON A SEPARATE PAGE.

1. **Time to complete questionnaire?** _______ minutes.

2. **Effort to complete the questionnaire?**
   1. Easy
   2. Medium
   3. Tedium

3. **Overall, did the presentation of the questionnaire (font, layout, use of whitespace) make it readable?**
   1. Yes
   0. No

4. **Overall, were instructions clear, concise and specific/unambiguous?**
   1. Yes
   0. No

5. **Overall, were questions clear, concise and specific/unambiguous?**
   1. Yes
   0. No

6. **Overall, were answers directly related to what the questions probed?**
   1. Yes
   0. No

7. **Overall, did answers encompass all expected choices?**
   1. Yes
   0. No

8. **How can this questionnaire be improved? Please provide specific suggestions if possible on the presentation, instructions, questions and answers used in this questionnaire.**
### SECTION V

In this section we will ask you some questions about your personal experience with lung cancer and lung cancer screening. Please circle the number that corresponds with your answer for each question.

1. **Have you or anyone close to you ever been diagnosed with lung cancer?**
   - 1 Yes
   - 0 No

   Please answer the following questions as appropriate.

2. **If you are a smoker:**
   - Have you sought (or will you seek) lung cancer screening for yourself?
     - 1 Yes
     - 0 No

3. **If you are not a smoker and have no other risk factors for lung cancer:**
   - Have you sought (or will you seek) lung cancer screening for yourself?
     - 1 Yes
     - 0 No

### SECTION II

In this section we will ask you some questions to find out what factors influence how you make lung cancer screening decisions with respect to asymptomatic patients. Please circle your response for each question.

1. In your practice, for asymptomatic patients who are never-smokers:
   a. How often do you estimate you would routinely (every 1 or 2 years) screen for lung cancer?
      - 0% 1-20% 21-40% 41-60% 61-80% 81-100%
   b. What screening test(s) for lung cancer do you order?
      - CXR  CT Chest  Sputum cytology  None
   c. Re. question 1 (b) above, how often do you estimate you would order a chest x-ray as a percentage of your lung cancer screening tests?
      - 0% 1-20% 21-40% 41-60% 61-80% 81-100%

2. In your practice, for asymptomatic patients with smoking as a risk factor (i.e. current/past smokers):
   a. How often do you estimate you would routinely (every 1 or 2 years) screen for lung cancer?
      - 0% 1-20% 21-40% 41-60% 61-80% 81-100%
   b. What screening test(s) for lung cancer do you order?
      - CXR  CT Chest  Sputum cytology  None
   c. Re. question 2 (b) above, how often do you estimate you would order a chest x-ray as a percentage of your lung cancer screening tests?
      - 0% 1-20% 21-40% 41-60% 61-80% 81-100%
Please circle the response that corresponds with the extent to which you agree or disagree with each of the following statements about lung cancer screening:

3. The guidelines for lung cancer screening are just guidelines. They are not absolute clinical rules.
   - STRONGLY AGREE
   - AGREE
   - DISAGREE
   - STRONGLY DISAGREE

4. I apply lung cancer screening guidelines to each individual patient's needs.
   - STRONGLY AGREE
   - AGREE
   - DISAGREE
   - STRONGLY DISAGREE

5. I tend to follow lung cancer screening guidelines when they are published by an organization that I trust.
   - STRONGLY AGREE
   - AGREE
   - DISAGREE
   - STRONGLY DISAGREE

6. If I missed a case of lung cancer I would tend to screen more patients for that particular disease for some time afterwards.
   - STRONGLY AGREE
   - AGREE
   - DISAGREE
   - STRONGLY DISAGREE

7. I will routinely recommend a lung cancer screening test when there is insufficient evidence, in order to avoid medical -legal repercussions.
   - STRONGLY AGREE
   - AGREE
   - DISAGREE
   - STRONGLY DISAGREE

8. I will routinely recommend a lung cancer screening test for patients if there is a positive history of smoking.
   - STRONGLY AGREE
   - AGREE
   - DISAGREE
   - STRONGLY DISAGREE

9. I will routinely recommend a lung cancer screening test for patients if there is a positive family history of lung cancer.
   - STRONGLY AGREE
   - AGREE
   - DISAGREE
   - STRONGLY DISAGREE

10. I will routinely recommend a lung cancer screening test for asymptomatic patients when there is a history of occupational exposure to asbestos, silica, or other chemicals.
    - STRONGLY AGREE
    - AGREE
    - DISAGREE
    - STRONGLY DISAGREE

11. I will routinely recommend a lung cancer screening test when patients have co-morbid conditions such as COPD.
    - STRONGLY AGREE
    - AGREE
    - DISAGREE
    - STRONGLY DISAGREE

SECTION IV

IN THIS SECTION WE WILL ASK YOU SOME QUESTIONS ABOUT YOU AND YOUR PRACTICE.

Please circle the number that corresponds with your answer for each question.

1. What is your gender?
   1. Male
   2. Female

2. What is your age group?
   1. 20-29 years
   2. 30-39 Years
   3. 40-49 years
   4. 50-59 years
   5. 60-69 years

3. Do you have Certification (CCFP) in the College of Family Physicians of Canada?
   1. Yes
   0. No

4. Are you a member of the College of Family Physicians of Canada?
   1. Yes
   0. No

5. How long have you been in practice?
   ________ years

6. Are you in a group practice?
   1. Yes
   0. No

7. In what type of community is your practice located?
   1. Urban setting
   2. Rural setting
   3. Regional Setting

8. How many hours per week do you see patients in your office(s) (not in hospital or emergency)?
   ________ hours per week

9. Do you have a teaching affiliation?
   1. Yes
   0. No
Scenario #5

Mr. Frank Tonelli is a 52 year old who you have a poor relationship with. He rarely sees doctors because he has little trust in them. He needs a “full physical” for a life insurance application. He has no current health problems. He has a smoking history, no family history of lung cancer and has no occupational exposure and is not worried about having the disease. His examination is normal.

Based on the information above, at the end of the visit what will you do?

<table>
<thead>
<tr>
<th>Screening Manoeuvre</th>
<th>Order</th>
<th>Not Order</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chest X-ray</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>CT Chest</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Sputum Cytology</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Other: ______________</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>

Scenario #6

Mrs. Ina Shants is a 41 year old difficult patient who you find challenging to work with. She often presents with unrealistic expectations regarding her care. Recently a friend of hers was diagnosed with lung cancer at age 43. This has increased her anxiety about her own chances of having lung cancer. She has a smoking history. Her father died of lung cancer at age 60. She wants to have a screening test done right away. She is healthy and has no previous history of lung disease. The clinical lung examination is entirely normal.

Based on the information above, at the end of the visit what will you do?

<table>
<thead>
<tr>
<th>Screening Manoeuvre</th>
<th>Order</th>
<th>Not Order</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chest X-ray</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>CT Chest</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Sputum Cytology</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Other: ______________</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>
SECTION III

IN THIS SECTION WE WILL ASK YOU TO INDICATE WHETHER OR NOT YOU WOULD ORDER A LUNG CANCER SCREENING TEST IN THE FOLLOWING DIFFERENT CLINICAL SCENARIOS.

Note: in the following scenarios, all patients are asymptomatic, current/past smokers.

Please check the box(es) that correspond with your answer for each question.

Scenario #1

Mr. Tom Eastman is a 56 year old male who has been consulting you for his hypertension which is well controlled with a beta blocker. He is a patient who you know well and have a good rapport with. He is scheduled today for a regular hypertension follow-up exam. He has heard of lung cancer screening tests from friends at work and wonders if you think he should have one done. He has a smoking history, no family history of lung cancer and has no occupational exposure and is not worried about having the disease. His blood pressure is 132/83 and the remainder of the examination is normal.

Based on the information above, at the end of the visit what will you do?

<table>
<thead>
<tr>
<th>Screening Manoeuvre</th>
<th>Order</th>
<th>Not Order</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chest X-ray</td>
<td>♡</td>
<td>☐</td>
</tr>
<tr>
<td>CT Chest</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Sputum Cytology</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Other: _____________</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>

Scenario #2

Mrs. Stephanie Myers is a 46 year old patient with whom you have an open and trusting relationship. At this visit she is requesting a screening test after reading on the Internet the high morbidity and mortality of lung cancer. Upon discussion you learn that she is not worried about her risk of lung cancer but rather sees the test as her right. She is healthy, has a smoking history, no family history of lung cancer or occupational exposure and no other related risk factors. The functional inquiry is negative for weight loss, cough and anorexia. The clinical lung examination is normal.

Based on the information above, at the end of the visit what will you do?

<table>
<thead>
<tr>
<th>Screening Manoeuvre</th>
<th>Order</th>
<th>Not Order</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chest X-ray</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>CT Chest</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Sputum Cytology</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Other: _____________</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>

Scenario #3

Mr. Vince de Ville is a 54 year old patient who you have a good relationship with. He is scheduled today for an annual check-up. He is quite anxious about his health and has brought in several articles off the Internet on lung cancer. He has a smoking history, no occupational exposure and his family history is negative for lung cancer. He is healthy and has no positive findings for lung cancer problems on physical exam.

Based on the information above, at the end of the visit what will you do?

<table>
<thead>
<tr>
<th>Screening Manoeuvre</th>
<th>Order</th>
<th>Not Order</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chest X-ray</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>CT Chest</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Sputum Cytology</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Other: _____________</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>

Scenario #4

Ms. Jenny Hill is a 53 year old who you have a good relationship with. She needs a “full physical” for a life insurance application. She has no current health problems. She has a smoking history. Her father died of lung cancer at age 60 but has no occupational exposure and is not worried about having the disease. The clinical lung examination is normal.

Based on the information above, at the end of the visit what will you do?

<table>
<thead>
<tr>
<th>Screening Manoeuvre</th>
<th>Order</th>
<th>Not Order</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chest X-ray</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>CT Chest</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Sputum Cytology</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Other: _____________</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>
Appendix B
Letter of Information
Letter of Information

Lung Cancer Screening Practices of Family Physicians in Saskatchewan

Introduction and Purpose of Study:

You are invited to participate in a study to explore your ideas, thoughts and experiences as a practicing family physician in Saskatchewan. The purpose of this letter is to provide you with the information you require to make an informed decision on participating in this research.

Who Can Participate:

You are invited to participate in this research if you are a practicing family physician in Saskatchewan. In order to be eligible to participate you must be between the ages of 25-65.

What Will the Study Involve:

Phase I of the study is a census survey to explore lung cancer screening practices.

In Phase II of the study, you may be invited to participate in an individual interview. The interview will take place at a location and time that is convenient for you and will take approximately thirty to forty-five minutes. The interview will be audio taped and transcribed verbatim.

Confidentiality and Privacy:

All information for the study is confidential. Each participant is assigned an ID number. All participant identifiers and ID numbers will remain in a master list in a password-protected database. The master list will remain separate from the data. The master list linking participant names to identifiers will be held separately from the data set and password protected or locked in a separate location (hard copy). The voice file of the interview will be sent off-site to a professional transcriptionist to be transcribed verbatim. If you use any names during the interview, they will be not transcribed but simply replaced with the word "name" or "place" (e.g. John = "name"). All electronic files will be password protected. All hardcopy forms and transcripts will be stored in a locked filing cabinet for security.
**Voluntary Participation:**

Participation in this study is voluntary. You may refuse to participate, refuse to answer any questions or withdraw from the study at any time.

**Risks and Benefits:**

We see no risks associated with this research. The benefits include gaining a better understanding of the challenges you face regarding screening decisions for lung cancer and to influence improvements in this aspect of practice.

**Do You Have Questions:**

If the results of the study are published, your name will not be used and no information that discloses your identify will be released or published without your explicit consent to the disclosure.

If you have any questions about your rights as a research participant or the conduct of the study, please contact Dr. David Hill, Scientific Director, Lawson Research Institute at (###) ###-####. Representatives of The University of Western Ontario Health Sciences Research Ethics Board may require access to your study-related records or may follow up with you to monitor the conduct of the research.

If you have any questions regarding your participation in this study, please contact Dr. John Feightner, Principal Investigator at (###) ###-####

Thank you for your consideration.

Dr. John Feightner
Professor

Dr. Judith Belle Brown
Professor

Centre for Studies in Family Medicine
Department of Medicine
Schulich School of Medicine & Dentistry
Appendix C
Analysis of Tudiver Survey Instrument

C.1 Analysis

The sample questionnaire, appended to this discussion, was provided by Dr Tudiver for review. It has the following structural attributes.

1. Section I – Questions about perceptions of current cancer screening guidelines
2. Section II – Questions about which factors influence cancer screening decisions
3. Section III – Clinical vignettes (two vignettes/cancer screen, six total) to inquire about decision to order cancer screening tests with variations in 4 patient factors
4. Section IV – Questions about respondent physician and practice characteristics
5. Section V – Questions about respondents personal experience with cancer and cancer screening

Note that the literature refers to a two-part survey, where Part 1 includes Sections I, II, IV and V and Part 2 includes Section III. A fractional factorial design ensured that each physician received a unique questionnaire – Part 1 was common to all questionnaires but Part 2 was unique. Part 2 of the sample questionnaire had the following notable features:

1. Two prostrate cancer screening vignettes, males only, alternated good/bad patient/physician relationship
2. Two breast cancer screening vignettes, females only, alternated good/bad patient physician relationship
3. Two colorectal cancer screening vignettes, female, male, alternated good/bad patient physician relationship
4. The structure of each vignette modelled the flow of information/activity in a clinical encounter. In addition, the style of writing employed expressed the level of each of the four patient factors being investigated in a clinically meaningful manner. Sequentially, patient/physician relationship factor was explained first, then reason for the patients visit with relevance to specific cancer screening, then medical history factor (personal, family, risk factors), then patient factors
(expectation of screening test, significant anxiety) and then asymptomatic clinical examination results.

Overall, Section III implemented a fractional, factorial design with six clinical scenarios, each representing a frame (which set the context) and each having 16 variations representing all possible combinations of the four patient factors (independent variables). Six frames implies $6 \times 16 = 96$ vignettes were required in the end and many more written during the iterative development/edit phase. The fractional factorial design required the unique series always had one vignette with all patient factors present, one with no patient factors present, and a random variation in patient factors in the remainder. The vignettes were presented in random order to minimize sequence bias. It appears that the frame position was fixed (Scenario #1-#6) so randomness must have been introduced by which patient factor combination would appear in which frame.

The clinical case vignettes were developed and tested in 4 steps.

1. Initially authored by the clinical investigators based on their experience.

2. Submitted to 12 family physicians colleagues for empirical review of descriptions.

3. Minimum of 9/12 (75%) had to correctly identify the intended level of each patient factor, else modified or replaced.

Those requiring correction were submitted to another set of 12 physicians to filter again according to 75% rule above.
Appendix D
Tudiver Survey Instrument
A NATIONAL STUDY OF HOW FAMILY PHYSICIANS MAKE CANCER SCREENING DECISIONS

FAMILY HEALTHCARE RESEARCH UNIT
DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE
UNIVERSITY OF TORONTO
SECTION I

In this section we will ask you some questions about your perception of the current guidelines for screening asymptomatic patients with no risk factors for cancer.

In this section "current guidelines" refers to any guidelines that you may have read regardless of the organization or country they were published by.

Please circle the number that corresponds with your answer for each question.

1a. What do you perceive the current guidelines for screening for prostate cancer with Prostate-Specific Antigen (PSA) say for asymptomatic men over age 50 with no risk factors?
   1 Screen with PSA is recommended.
   2 Screen with PSA is not recommended.
   3 It is unclear whether PSA should be recommended.

1b. Do you consider the current guidelines for screening for prostate cancer with Prostate-Specific Antigen (PSA) of asymptomatic men over age 50 with no risk factors to be conflicting (i.e. two or more organizations have different views)?
   1 Yes
   0 No

2a. What do you perceive the current guidelines for screening for breast cancer with mammography say for asymptomatic women age 40 to 49 with no risk factors?
   1 Screening with mammography is recommended.
   2 Screening with mammography is not recommended.
   3 It is unclear whether mammography should be recommended.

2b. Do you consider the current guidelines for screening for breast cancer with mammography of asymptomatic women age 40 to 49 with no risk factors to be conflicting (i.e. two or more organizations have different views)?
   1 Yes
   0 No

3a. What do you perceive the current guidelines for screening for colorectal cancer with Fecal Occult Blood (FOBT) say for asymptomatic patients over age 40 with no risk factors?
   1 Screening with FOBT is recommended.
   2 Screening with FOBT is not recommended.
   3 It is unclear whether screening with FOBT should be recommended.

3b. Do you consider the current guidelines for screening for colorectal cancer with Fecal Occult Blood (FOBT) of asymptomatic patients over age 40 with no risk factors to be conflicting (i.e. two or more organizations have different views)?
   1 Yes
   0 No

4a. What do you perceive the current guidelines for screening for colorectal cancer with colonoscopy say for asymptomatic patients over age 40 with no risk factors?
   1 Screening with colonoscopy is recommended.
   2 Screening with colonoscopy is not recommended.
   3 It is unclear whether screening with colonoscopy should be recommended.

4b. Do you consider the current guidelines for screening for colorectal cancer with colonoscopy of asymptomatic patients over age 40 with no risk factors to be conflicting (i.e. two or more organizations have different views)?
   1 Yes
Section II

In this section we will ask you some questions to find out what factors influence how you make cancer screening decisions with respect to asymptomatic patients with no risk factors.

Please circle the response that corresponds with the extent to which you agree or disagree with each of the following statements about cancer screening.

1. The guidelines for cancer screening are just guidelines. They are not absolute clinical rules. [Strongly Agree] Agree Disagree Strongly Disagree

2. I apply cancer screening guidelines to each individual patient's needs. [Strongly Agree] Agree Disagree Strongly Disagree

3. I tend to follow cancer screening guidelines when they are published by an organization that I trust. [Strongly Agree] Agree Disagree Strongly Disagree

4. If I missed a case of cancer, I would tend to screen more patients for that particular disease for some time afterwards. [Strongly Agree] Agree Disagree Strongly Disagree

5. I will order a cancer screening test when the guidelines are unclear to avoid medical-legal repercussions. [Strongly Agree] Agree Disagree Strongly Disagree

6. I will recommend PSA for men over age 50 if there is a positive family history of prostate cancer. [Strongly Agree] Agree Disagree Strongly Disagree

7. I do not recommend PSA for men over age 50 because I think it has the potential to cause more harm than good. [Strongly Agree] Agree Disagree Strongly Disagree

8. I do not recommend mammography for women age 40 to 49 because I think it has the potential to cause more harm than good. [Strongly Agree] Agree Disagree Strongly Disagree

9. I do not recommend FOBT for patients over age 40 because I think it has the potential to cause more harm than good. [Strongly Agree] Agree Disagree Strongly Disagree

10. I do not recommend colonoscopy for patients over age 40 because I think it has the potential to cause more harm than good. [Strongly Agree] Agree Disagree Strongly Disagree
11. I will order a cancer screening test that I do not usually recommend if:
   
a) A patient is anxious about having the disease.  
   
   `| STRONGLY | AGREE | DISAGREE | STRONGLY | DISAGREE |
   |        |       |          |         |
   
   b) A patient requests the test and insists on having it done.  
   
   `| STRONGLY | AGREE | DISAGREE | STRONGLY | DISAGREE |
   |        |       |          |         |
   
   c) I hear that my colleagues are recommending it to their patients.  
   
   `| STRONGLY | AGREE | DISAGREE | STRONGLY | DISAGREE |
   |        |       |          |         |
   
   d) Specialists I work with recommend ordering the test.  
   
   `| STRONGLY | AGREE | DISAGREE | STRONGLY | DISAGREE |
   |        |       |          |         |
   
   e) The test is inexpensive.  
   
   `| STRONGLY | AGREE | DISAGREE | STRONGLY | DISAGREE |
   |        |       |          |         |
   
   f) The test is easily accessible.  
   
   `| STRONGLY | AGREE | DISAGREE | STRONGLY | DISAGREE |
   |        |       |          |         |
   
   g) The test is easy to administer.  
   
   `| STRONGLY | AGREE | DISAGREE | STRONGLY | DISAGREE |
   |        |       |          |         |
   
   h) The test will take less time to order than to convince a patient they do not need it.  
   
   `| STRONGLY | AGREE | DISAGREE | STRONGLY | DISAGREE |
   |        |       |          |         |

---

**SECTION III**

_**IN THIS SECTION WE WILL ASK YOU TO INDICATE WHETHER OR NOT YOU WOULD ORDER A CANCER SCREENING TEST IN SIX DIFFERENT CLINICAL SCENARIOS.**_

Please circle the number that corresponds with your answer for each question.

**Scenario #1**

Mr. Tom Eastman is a 56 year old male who has been consulting you for his hypertension which is well controlled with a beta blocker. He is a patient who you know well and have a good rapport with. He is scheduled today for a regular hypertension follow-up exam. He has heard of the PSA test from friends at work and wonders if you think he should have one done. He has no urinary problems. He has no family history of prostate cancer and is not worried about having the disease. His blood pressure is 132/83 and the remainder of the examination is normal.

Based on the information above, at the end of the visit what will you do?

1. Order a PSA test  
0. Not order a PSA test

**Scenario #2**

Mr. Vince de Ville is a 54 year old patient who you have a poor relationship with. He is difficult to interact with because he is very demanding and expects you "to do things his way". He is scheduled today for an annual check-up. He is quite anxious about his health and has brought in several articles off the Internet on prostate cancer. He demands to have a PSA test done. His family history is negative for prostate cancer. He is healthy and has no positive findings for prostate problems on physical exam.
Based on the information above, at the end of the visit what will you do?

1  Order a PSA test
0  Not order a PSA test

Scenario #3

Mrs. Ina Shantz is a 41 year old with whom you have an open and trusting relationship. Recently a friend of hers was diagnosed with breast cancer at age 43. This has increased her anxiety about her own chances of having breast cancer. Her mother died of breast cancer at age 57. She wants to have a mammogram done right away. She has two children. She is healthy and has no previous history of breast disease. The clinical breast examination is entirely normal.

Based on the information above, at the end of the visit what will you do?

1  Order a mammogram
0  Not order a mammogram

Scenario #4

Mrs. Stephanie Myers is 46 years of age. She is a difficult patient who you find challenging to work with. She often presents with unrealistic expectations regarding her care. At this visit she is requesting a mammogram after reading on the Internet that all women should start having mammograms at age 40. Upon discussion you learn that she is not worried about her risk of breast cancer but rather sees the test as her right. She has three children. She is healthy, has no family history of breast cancer and no other related risk factors. The clinical breast examination is normal.

Based on the information above, at the end of the visit what will you do?

1  Order a mammogram
0  Not order a mammogram

Scenario #5

Ms. Janice Gibson is a 48 year old healthy woman who you find easy going and pleasant to care for. She is very concerned about her own health having just learned about a 56 year old neighbor who had a colostomy due to colon cancer. She wants to be tested immediately. Although you explain the risks involved she still insists on being tested. She has no family history of colorectal cancer nor any significant findings during the functional enquiry.

Based on the information above, at the end of the visit what will you do?

a) 1  Order a FOBT
    0  Not order a FOBT

b) 1  Order a colonoscopy
    0  Not order a colonoscopy

Scenario #6

Mr. Frank Tonelli is a 52 year old who you have a poor relationship with. He rarely sees doctors because he has little trust in them. He needs a "full physical" for a life insurance application. He has no current health problems. Upon obtaining a family history you learn that his older brother, age 55, has recently been diagnosed with an "early form of colon cancer". However, Mr. Tonelli is not worried that he is at risk and does not expect any specific testing with regard to colorectal cancer. The functional enquiry is negative for blood in the stool, abdominal pain, chronic constipation or changes in bowel habit.

Based on the information above, at the end of the visit what will you do?
a) 1 Order a FOBT
    0 Not order a FOBT

b) 1 Order a colonoscopy
    0 Not order a colonoscopy

SECTION IV

IN THIS SECTION WE WILL ASK YOU SOME QUESTIONS ABOUT YOU AND YOUR PRACTICE.

Please circle the number that corresponds with your answer for each question.

1. What is your gender?
   1 Male
   2 Female

2. What is your age?
   _____ years

3. Do you have Certification (CCFP) in the College of Family Physicians of Canada?
   1 Yes
   0 No

4. Are you a member of the College of Family Physicians of Canada?
   1 Yes
   0 No

5. How long have you been in practice?
   _____ years

6. Are you in a group practice?
   1 Yes
   0 No

7. What is the population size of the city in which you practice?
   1 1,000,000 or more
   2 500,000 to 999,999
   3 100,000 to 499,999
   4 25,000 to 99,999
   5 Less than 25,000

8. How many hours per week do you see patients in your office(s) (not in hospital or emergency)?
   _____ hours per week

9. Do you have a teaching affiliation?
   1 Yes
   0 No
SECTION V

In this section we will ask you some questions about your personal experience with cancer and cancer screening.

Please circle the number that corresponds with your answer for each question.

1. Have you or anyone close to you ever been diagnosed with cancer?
   1   Yes
   0   No

Please answer the following questions according to your gender and age if appropriate.

2. If you are male and age 50 or older:
   Have you sought (or will you seek) prostate cancer screening with PSA for yourself?
   1   Yes
   0   No

3. If you are female and age 40 to 49:
   Have you sought (or will you seek) breast cancer screening with mammogram for yourself?
   1   Yes
   0   No

4. If you are age 40 or older:
   Have you sought (or will you seek) colorectal cancer screening with FOBT for yourself?
   1   Yes
   0   No

5. If you are age 40 or older:
   Have you sought (or will you seek) colorectal cancer screening with colonoscopy for yourself?
   1   Yes
   0   No
THANK YOU FOR COMPLETING THIS QUESTIONNAIRE.

PLEASE RETURN THE QUESTIONNAIRE IN THE ENCLOSED ENVELOPE TO:

FAMILY HEALTHCARE RESEARCH UNIT
DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE
UNIVERSITY OF TORONTO

Your comments are appreciated, either here or on a separate page.
Appendix E
Detailed Methods for Questionnaire Development

E.1 Questionnaire Design Methodology

The following describes the approach taken to develop this study’s survey instrument, a questionnaire adapted from the Tudiver et al. survey tool. The Tudiver et al. study explored factors that influence cancer screening decision-making for prostate, breast and colorectal cancer. Since the current study objectives were focussed specifically on lung cancer screening, the methodology used in this study was unique.

The Tudiver et al. survey instrument was adapted to fulfil the new study objectives. Their survey tool had questions on prostate, colorectal and breast cancer. They were replaced with questions specifically about lung cancer screening. Questions were also added to estimate the proportion of physicians screening by self-report and to identify which tests were preferred.

E.2 Questionnaire Items

The questionnaire developed for this study was a derivation of the validated survey instrument used by Tudiver et al.²,10,53 with modifications to adapt it to study how family physicians make lung cancer screening decisions. The questionnaire is composed of 38 single item questions (some with multiple answer subparts) and six clinical case vignettes, organized into five sections:

I. Physician perceptions of guidelines for lung cancer screening;

II. Inquiry into which medical and non-medical factors influence the participating physician’s lung cancer screening decisions;

III. Clinical case vignettes to study the influence of factors (patient anxiety, expectation, positive family history) on family physicians lung cancer screening behaviour;

IV. Practice characteristics and physician demographics;
V. Physician’s personal experiences with lung cancer and lung cancer screening behaviour;

VI. Survey Evaluation to obtain respondent feedback on validity and reliability.

E.2.1 Section II Items to classify physicians as Screeners or Non-Screeners

The survey collected data needed to classify participants into two groups – Screeners and Non-screeners. Direct query was chosen to minimize error and introductory questions (Section II, Q1 and Q2) were developed to examine screening behaviour. The following discussion references the actual questionnaire attached as an appendix.

Questions 1 and 2 are identical except they address screening behaviour for two groups, non-smokers and current or past smokers. This broadens the survey to include screening behaviour towards non-smokers who sometimes develop lung cancer. Non-smokers are defined as patients who have never smoked. Current or past smokers are patients who currently smoke or have past history of smoking.

Questions 1a and 2a are ratio scale questions. The data they provide have a true zero value and were treated as ratio data. We are soliciting ratio data with what appears to be an ordinal scale with response options presented in ranges. Ranges are presented because it’s faster for the respondent to answer the question, lowering respondent burden. Less respondent burden will promote a higher rate of return which enhances the external validity of the study.

Question 1b and 2b are nominal scale questions added to collect data on ordering behaviour for all types of lung cancer screening tests.

Question 3-14 are ratio scale questions. The data they provided have a true zero value and were treated as ratio data. A 4-point Likert scale was used to ease data collection.
E.2.2 Section III Clinical Case Vignettes

The Tudiver et al questionnaire\textsuperscript{53} made use of clinical case vignettes noting “they have been shown to be a useful, inexpensive, and effective method for eliciting physicians’ decision-making behaviour in a simulated situation”.\textsuperscript{85} Peabody concluded that clinical case vignettes appear to be a valid and comprehensive method to focus on actual clinical practice in an outpatient setting, rather than physician competence.\textsuperscript{85} Their prospective study ranked the relative effectiveness of the methods studied as:

1) Standardized patients, 2) clinical case vignettes and 3) chart abstraction. Case vignettes have been used to examine physicians’ practice behaviour with cancer patients.\textsuperscript{90-93}

Tudiver\textsuperscript{53} stated “For research purposes, the usefulness of the clinical case vignette rests on the ability to vary specific factors (relevant independent variables under study) from one vignette to another, while keeping constant the surrounding factors of the case presented (the frame).” The same rationale applies to the revised clinical case vignettes developed for the study questionnaire.

The survey included 6 clinical case vignettes developed by one of the clinician investigators (NJ). The vignettes vary the patient factors (independent variable) shown in Table 1, with the dependent variable being a yes/no decision to order any of the three screening tests (CXR, CT Chest, Sputum Cytology).

<table>
<thead>
<tr>
<th>Patient Factor</th>
<th>Factor Present in Clinical Vignette</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scenario #1 (Control)</td>
<td>Scenario #2</td>
</tr>
<tr>
<td>Patient expects to undergo screening</td>
<td>Y</td>
</tr>
<tr>
<td>Patient anxious about having lung cancer</td>
<td></td>
</tr>
<tr>
<td>Positive family history of lung cancer</td>
<td></td>
</tr>
</tbody>
</table>

Table 1 Patient Factors Present in Clinic Vignettes
<table>
<thead>
<tr>
<th>Patient Factor</th>
<th>Factor Present in Clinical Vignette</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poor quality physician-patient</td>
<td></td>
</tr>
<tr>
<td>relationship</td>
<td></td>
</tr>
<tr>
<td>(Control)</td>
<td></td>
</tr>
<tr>
<td>Scenario #1</td>
<td>(Control)</td>
</tr>
<tr>
<td>Scenario #2</td>
<td></td>
</tr>
<tr>
<td>Scenario #3</td>
<td></td>
</tr>
<tr>
<td>Scenario #4</td>
<td></td>
</tr>
<tr>
<td>Scenario #5</td>
<td>Y</td>
</tr>
<tr>
<td>Scenario #6</td>
<td>Y</td>
</tr>
</tbody>
</table>

### E.3 Reliability and Validity

To ensure validity and to ensure appropriateness of the reading level, the survey was piloted on three family physicians. This was followed by an interview to improve clarity and comprehensiveness of the questionnaire. This feedback led to changes to two questions about physician demographics: age was obtained as a range instead of an actual age; type of practice was broadened to add Regional to existing Rural & Urban choices.

This study also contains a section to test actual physician behaviour in a simulated clinical setting by means of a clinical experimental study component, consisting of clinical case vignettes where testing is done in the context of a controlled environment, one where independent variables are manipulated to examine decision-making behaviour. The scenarios presented are intended to model real-world clinical encounters, enhancing external validity.

References on questionnaire design and quality assessment were consulted during questionnaire development59-68.

To increase the external validity of the study, a high rate of return was desired. This was promoted in this study by applying best practices identified in the literature including administration of the survey using the step-wise revised Dillman Method.58
Appendix F
Ethics Approval
Use of Human Participants - Ethics Approval Notice

Principal Investigator: Dr. John Freightner
Review Number: 17272E
Review Level: Delegated
Approved Local Adult Participants: 0
Approved Local Minor Participants: 0
Protocol Title: How Family physicians in western Manitoba make lung cancer screening decisions
Department & Institution:
Sponsor:
Ethics Approval Date: January 13, 2012
Expiry Date: June 30, 2012
Documents Reviewed & Approved & Documents Received for Information:

<table>
<thead>
<tr>
<th>Document Name</th>
<th>Comments</th>
<th>Version Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revised UWO Protocol</td>
<td>The location of the student researcher has changed.</td>
<td></td>
</tr>
<tr>
<td>Revised Letter of Information &amp;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Consent</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This is to notify you that The University of Western Ontario Research Ethics Board for Health Sciences Research Involving Human Subjects (HSREB) which is organized and operates according to the Tri-Council Policy Statement: Ethical Conduct of Research Involving Humans and the Health Canada/ICH Good Clinical Practice Practices: Consolidated Guidelines; and the applicable laws and regulations of Ontario has reviewed and granted approval to the above referenced revision(s) or amendment(s) on the approval date noted above. The membership of this REB also complies with the membership requirements for REB's as defined in Division 5 of the Food and Drug Regulations.

The ethics approval for this study shall remain valid until the expiry date noted above assuming timely and acceptable responses to the HSREB’s periodic requests for surveillance and monitoring information. If you require an updated approval notice prior to that time you must request it using the UWO Updated Approval Request Form.

Members of the HSREB who are named as investigators in research studies, or declare a conflict of interest, do not participate in discussion related to, nor vote on, such studies when they are presented to the HSREB.

The Chair of the HSREB is Dr. Joseph Gilbert. The UWO HSREB is registered with the U.S. Department of Health & Human Services under the IRB registration number IRB 00000940.

Signature

________________________

Ethics Officer to Contact for Further Information

| Janice Sutherland | Grace Kelly | Shantel Walcott |

This is an official document. Please retain the original in your files.

The University of Western Ontario
Office of Research Ethics
Appendix G
Curriculum Vitae
CURRICULUM VITAE - NUSRAT JAMIL

Licensure

The College of Family Physicians of Canada
Certification in Family Medicine (CCFP)

Medical Council of Canada
Licentiate Medical Council of Canada (LMCC)

Education Commission for Foreign Medical Graduates (ECFMG)
ECFMG

College of Physicians and Surgeons of Saskatchewan
Licence to practice Medicine in the Province of Saskatchewan

Certifications

- Advanced Trauma Life Support (ATLS)
- Advanced Cardiac Life Support (ACLS)
- Neonatal Resuscitation Procedure (NRP)
- Pediatric Advanced Life Support (PALS)
- Procedural Sedation
- Certification in Higher Education Teaching (CHET), Faculty of Graduate Studies, University of Manitoba

Education

Master of Clinical Science in Family Medicine (Thesis)
Department of Family Medicine, University of Western Ontario

Courses Completed:
- Advanced Patient Centred Medicine
- Research Methods in Family Medicine
- Teaching and Learning in the Health Sciences
- Theoretical Foundations of Family Medicine
- Clinical and Teaching Practicum
- Meet the Researchers Seminar Series
- Thesis Research

Certification in Higher Education Teaching (CHET)
Faculty of Medicine and Faculty of Graduate Studies, University of Manitoba, January, 2005
First Physician to obtain certification in history of program
Research and Academic Skills Development Fellowship
Department of Family Medicine, University of Manitoba, Jan 2006

Teaching Experience:
- Preceptor for Undergraduate Med I and II Clinical Skills Labs/Workshops

Courses Attended:
- Teaching Dossier and Promotion and Tenure
- TIPS
- Workshops for Clinical Research, SBGH Office of Clinical Research:
  - Introduction to Clinical Research
  - Guidelines, Policies and Regulations in the Conduct of Clinical Research
  - Project Management for Clinical Research
- Thesis Writing Seminar
- Teaching with PowerPoint
- Reference Manager

Family Medicine Residency
Department of Family Medicine, University of Manitoba, Jul 2002 to Jan 2005

Awards:

Courses:
- Advanced Trauma Life Support (ATLS)
- Advanced Cardiac Life Support (ACLS)
- Neonatal Resuscitation Procedure (NRP)
- Pediatric Advanced Life Support (PALS)
- Procedural Sedation
- Monthly Journal Clubs throughout Residency
- Physician as Teacher Series

Anaesthesia Residency
Department of Anaesthesiology
The Aga Khan University Hospital, Oct 1997 to Jan 1999

Rotating Internship
Departments of Medicine, Emergency, Surgery, Neurosurgery, Intensive Care and Anaesthesia
The Aga Khan University Hospital, Oct 1996 to Oct 1997

Externship in USA
Departments of Medicine, Cardiology, Endocrinology and Neurology
University of Minnesota, USA, Apr 1995 to Jul 1996

Conducted patient histories, physical exams, initial diagnoses and proposed treatment plans. Actively participated in Case Conferences and Case Presentations. Learned interpretation of Body CAT Scan. Researched and presented a specified weekly topic to staff, residents and students.

MBBS (Bachelor of Medicine and Bachelor of Surgery) Degree
Dow Medical College, Mar 1989 to Jun 1995
St. Joseph Convent College, Apr 1986 to Aug 1988
Teaching Experience

Postgraduate Teaching

- Medical Council of Canada
  - *Examiner* – MCC Qualifying Exam, 2014

- College of Family Physician’s of Canada

- University of Saskatchewan:
  - *Physician Champion* : Responsible for teaching licenced Family Physicians in Saskatchewan the curriculum of the College of Family Physician of Canada to attain certification
  - *Clinical Assistant Professor* – University of Saskatchewan, Community Faculty Appointment (2012 to present)

- University of Manitoba:
  - Speaker at Family Medicine Annual Residents Retreat at University of Manitoba 2009
  - Involved in Teaching Family Medicine Residents as a Fellow
  - Director Physician Mentorship Program Saskatchewan July 2009 to July 2011
  - Involved in Teaching and Evaluating Medical Students and Residents of University of Manitoba rotating through Emergency Medicine in Brandon
  - Mentoring and evaluating International Medical Graduates in Brandon Emergency Room for Manitoba Program for Licensing International Medical Graduates

Undergraduate Teaching

- *Guest Lecturer at University of Manitoba*
  - Courses taught:
    - Communication skills
    - Physical Examination labs
      - Respiratory System
      - Cardiovascular System
      - Abdominal Exam
      - Musculo-skeletal System
      - Central Nervous System

Teaching and Learning Portfolio

- Tips to improve bedside teaching in the clinical training unit
- Tips for teaching in large and small groups
- Tips for teaching in the Ambulatory setting- A primer for community preceptors
- Tips for assessment and evaluation in large and small groups
- Tips on resident assessment (Mentor Feedback)
Clinical Experience

Emergency Room Physician, January 2011 to Present
Yorkton Regional Health Centre

Family Physician, January 2009 to Present
Various Regional Health Authorities in Saskatchewan

Emergency Room Physician, July 2007 to April 2011
Brandon Regional Health Centre

Emergency Room Physician (Locum), November 2005 to 2012
Various sites in Manitoba

Family Physician (Locum), January 2009 to July 2011
Various sites in Saskatchewan

Community Family Physician Yorkton, August 2011 to Present
Private Practice

Research Experience

Lung Cancer Screening Practices of Family Physicians in Saskatchewan
Janus Research Grant from College of Family Physicians of Canada

Counseling Adolescents to Prevent Motor Vehicle Accidents
Qualitative method of in-depth interviews to study the perceptions of health care professionals about counseling adolescents for safe driving practices to prevent motor vehicle accidents in this population.

A study of Family Physician’s screening practices for lung cancer in smokers
Cross Sectional Study (chart audit)

Does breast feeding and aerobic exercise help in reducing weight? Are the results significantly different from non-breast feeding, exercising mothers?
Clinical Descriptive Research Proposal

STI Prevention Plan in Adolescents
Development of Proposal with the following objectives:
- To provide education and knowledge about safe sexual practices for prevention of STIs in adolescents in Family Medicine/Pediatric Clinics.
- To decrease morbidity rates secondary to STIs.

To study the efficacy and safety of two drugs – methylodopa and labetalol with the goal to achieve better control of PIH leading to better maternal and neonatal outcomes
Randomized control trial (double blind study)

Medical Consultant to Health Canada, Clinical Drug Trials, Jan 2000 - 2007
Centre for Biologics Evaluation, Clinical Evaluations Division, Health Canada, Ottawa

Research Experience in USA
Alzheimer’s Research Foundation, Minneapolis, Minnesota, USA., Oct 1995 to Aug 1996
Lab Study of drug administration by intra-nasal route via the cribriform bone, to increase drug concentration in the central nervous system, while minimizing peripheral side effects.
Public Health Experience

Director, Medical Aid and Domestic Violence Relief International, Ottawa July 2000
Founder of non-profit NGO, currently at project proposal and fundraising stage.
Director of Burn Unit Programs, International Network for the Rights of Victims of Violence in Pakistan, University of Louisville, USA, Oct 1999
Authored a Needs Assessment & Proposal for establishing a Burn Unit, for N.A. sponsorship.
Participation in other public health projects since pre-clinical years.
- Sind Institute Of Urology And Transplant - Organised international conferences
- Volunteered in Free Clinics for the underprivileged - Organised by Karwane Khair, an NGO based in Karachi, Pakistan. Clinic provided free screening for diabetes & hypertension, healthy lifestyle education.
- Organized & participated in social welfare activities at DOW Medical College, Aga Khan University Hospital

Administrative Positions:

- Physician Advisory Committee, Sunrise RHA (2011 to 2015)
- Regional Medical Advisory Committee, Sunrise RHA (2011 to 2015)
- Chief of Emergency Medical Services, Sunrise RHA (2011 to 2015)
- Vice Chairperson, Mental Health Services, Yorkton (2011 to 2015)
- Board Member PARIM - Professional Association of Residents In Manitoba.
- Urban-Member at Large(Former) - Manitoba Medical Association
- Director, Medical Aid and Domestic Violence Relief International (Former) - Ottawa

Memberships & Affiliations

- College of Family Physicians of Canada
- Saskatchewan Medical Association
- College of Family Physicians of Canada (Section of Teachers)
- College of Family Physicians of Canada (Section of Researchers)
- Doctors Manitoba
- Canada: Medical Aid and Domestic Violence Relief International, Canada

Honours and Awards

- College of Family Physicians and Canada - Janus Research Grant Award Year 2009
- University of Manitoba - Best Poster Presentation Award 2005
Conferences

- Faculty Development Seminars, University of Saskatchewan (SnoDocs), 2013,14&15
- North York General Emergency Medicine Update May 2009
- Faculty Development Seminars and Workshops University of Manitoba, 2008
- Communication skills workshop, Toronto July 2008
- MSK 2008, Whistler BC
- Emergency Medicine update 2008, Whistler BC
- Cancer Pro, Cancer Care Manitoba Brandon, Manitoba 2008
- North American Primary Research Group (NAPCRG), Banff, Oct 2003
- Family Medicine Forum, College of Family Physicians of Canada, Calgary, Oct 2003
- Family Medicine Forum, Manitoba College of Family Physicians, Winnipeg, Apr 2003